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INTRODUCTION 
This Working Paper has been prepared as support for the European Commission’s 
Communication to the European Parliament, the Council, the Committee of Regions and the 
Economic and Social Committee on Third Progress Report and Future Orientation on Life 
Sciences and Biotechnology.  
It aims to provide a detailed overview of the progress made in implementing the action plan 
set out in the Strategy. 
Actions are subdivided into four headings as follows: 
A)  Harvesting the potential (Actions 1-12):  
Actions under this heading aims at developing skills, supporting European research, 
providing a strong European intellectual property system, facilitating access to 
capital, networking all the various stakeholders working in biotechnology in Europe 
and increasing the proactive role of the public authorities.  
B)  A key element for responsible policy: governing life sciences and biotechnology 
(Actions 13-23):  
These actions include dialogue among stakeholders, ethical and social implications, 
consumers’ right to choose and the legislative framework.  
C)  Europe in the world – responding to global challenges (Actions 24-28):  
These actions highlight Europe’s role in developing international guidelines and 
indicate the areas where Europe can support the developing world in its efforts.  
D)  Implementation and coherence across policies, sectors and stakeholders 
(Actions 29 and 30):  
This final group of actions focuses on the role of the Commission in evaluating and 
further developing the Europe’s biotechnology policy in the coming years. 
1.  HARVESTING THE POTENTIAL  
1.1.  THE RESOURCE BASE  
1.1.1.  Investing in people 
1.1.1.1.  Identifying the education and training needs in Life Sciences 
Investment in human resources is at the heart of Education and Training policies for 
the knowledge based society.  
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In its Joint Interim Report of 2004 "Education and Training 2010"
1, the Council and 
the Commission emphasise the urgent need for reforms and to carry forward the Lisbon 
strategy much more resolutely. The objectives set for education and training in the 
detailed work programme adopted in 2002
2 remain fully valid for the years ahead.  
Three following levers of success should be acted upon simultaneously and without 
delay: 
•  Focus reform and investment on the key areas: a) mobilise the necessary 
resources effectively, and b) make the profession of teacher/trainer more 
attractive; 
•  Make lifelong learning a concrete reality; 
•  Establish a Europe of Education and Training. 
Furthermore, the Education Council adopted in May 2003 five European benchmarks 
in the field of Education and Training to be achieved by 2010
3. 
1.1.1.2.  Match a skilled workforce with job opportunities 
Amongst the 24 actions of the Action Plan for Skills and Mobility
4,  
•  action 2 seeks to promote maths, science and technology skills,  
•  action 4 seeks closer links between education, industry and careers guidance.  
•  Actions 23 and 24 address explicitly the issue of a one stop mobility and 
information/qualifications website, and the existing EURES website on the 
classification of professions 
The 2004 mid-term review of the Action plan
5 notes that with regard to actions 2 
and 4 further progress will have to be made whereas the one stop mobility website 
has been successfully launched in September 2003 and it’s now regularly attracting 
half a million visits each month. 
With the aim to ensure that as far as possible, mobility for education and training 
purposes will be a positive experience both in the host country and after return to the 
country of origin, the Commission is preparing a proposal for a second 
Recommendation of the European Parliament and of the Council on transnational 
mobility within the Community. 
The proposed Recommendation is a continuation to the Recommendation 
2001/613/EC of the European Parliament and of the Council of 10 July 2001 on 
mobility within the Community for students, persons undergoing training, 
                                                 
1  http://europa.eu.int/comm/education/policies/2010/doc/jir_council_final.pdf 
2  http://europa.eu.int/eur-lex/pri/en/oj/dat/2002/c_142/c_14220020614en00010022.pdf 
3 http://europa.eu.int/comm/education/policies/2010/doc/after-council-meeting_en.pdf 
4 COM(2002)  72 
5 COM(2004)  66  
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volunteers, teachers and trainers. It focuses on the quality aspects of mobility, and is 
entitled a “European Quality Charter for Mobility in Education and Training”. 
It is expected that the proposed Recommendation will contribute when adopted, to 
matching a skilled workforce with job opportunities. 
1.1.1.3.  Human resources in R&D: Researchers 
One key prerequisite for the effective realisation of greater investments in Life 
Sciences and Biotechnology research and, in particular the activation of private 
investment, is the availability of numerous, well trained and motivated researchers. 
This presupposes targeted efforts for providing researchers with attractive long term 
career perspectives, by improving the employment and working conditions, by 
making the “professions” in research and development more attractive and by 
creating more favourable conditions for every form of mobility within a given 
research career path. These issues are crucial because the way in which research 
careers are structured and organised in Europe as well as their fragmentation at local 
(national, regional) level, does not allow the full exploitation of the European 
potential in this field. 
In the frame of the integrated strategy the Commission has set into place to enhance 
the quality and quantity of researchers in Europe, and based on preparatory work 
including a wide consultation with stakeholders and Member States’ experts 
undertaken during 2004, the Commission has adopted in March 2005 a 
Recommendation to Member States on the European Charter for Researchers and 
a Code of Conduct for the recruitment of researchers
6. Together with the formal 
launch and unfolding across Europe of the ERA-MORE network of proximity 
assistance to mobile researchers in 2004, as well as the forthcoming Directive on the 
entry and stay in the EU of third country researchers, these are highlights of key 
steps towards the creation of a real European researchers’ labour market. The 
Commission has also started to create a dynamic overview of researchers’ stocks, in-
and outflows, career paths and geographical and inter-sectoral mobility flows, in both 
public and private sectors.  
The Commission published on 11 March 2005 a staff working document "Women in 
Science: Excellence and Innovation – Gender Equality in Science"
7 which outlines 
new and continuing priorities for future action both at Member State and European 
levels and suggests that, in terms of the participation of women in science, the 
objectives need now to be more narrowly focused, to concentrate essentially on 
women in decision-making positions and on certain disciplines or fields. 
1.1.2.  Generating and exploiting knowledge 
1.1.2.1.  Research 
A) Life Sciences and Biotechnology in the Sixth Framework programme 
                                                 
6  C(2005) 576  
7 SEC(2005)  370 
http://europa.eu.int/comm/research/science-society/pdf/documents_women_sec_en.pdf, annex: 
http://europa.eu.int/comm/research/science-society/pdf/documents_women_sec2_en.pdf  
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The 6
th Framework Programme for Research (FP6) is continuing to bring a strong 
impetus to Life Sciences and Biotechnology research in Europe, in particular in 
terms of critical mass of human and financial resources, sharing of knowledge and 
facilities, strengthening of scientific excellence, coordination of national activities 
and support to EU policies.  
Around €470 million have been awarded for "Life sciences, genomics and 
biotechnology for health" research in 2004. These funds will go to around 130 
projects, involving more than 1500 participants. This will bring to more than €1100 
million the EU contribution to research in this sector over the first two years 
(2003 and 2004) of FP6. Pursuing its effort in this field, the EC has published the 
next call for proposals with research priorities and an indicative budget of €1080 
million for the next two years 
Another €198 million have been awarded for food quality and safety research in 
2004. These funds will go to 44 projects, involving more than 850 participants. This 
will bring to €402 million the EU contribution to research in this sector over the 
first two years (2003 and 2004) of FP6. Pursuing its effort in this field, the EC has 
published the next call for proposals with research priorities and an indicative budget 
of €360 million for the next two years.  
The activities undertaken in the context of FP6 illustrate the broad application of Life 
Sciences and Biotechnology research to a large number of industrial sectors (e.g. 
health, food, agriculture, chemical…) and its continuing evolution integrating new 
and emerging disciplines such as the “omics” technologies (genomics, proteomics, 
metabolomics, glycomics…) as well as its converging with other technologies (nano, 
info, cognitive and social sciences). The “PATHFINDER” initiatives under the 
“New and Emerging Science and Technology” activities in FP6 identified “synthetic 
biology” as an emerging area in biotechnology expecting to be a standard approach 
in “ biotechnology of the year 2030”. These new challenges were also discussed at 
the workshop on "Future Challenges for Life Sciences Research" organised in 
September 2004 by the European Group on Life Sciences (EGLS)
8. On December 
2004, the European Commission organised the high-level conference: Funding 
Basic Research in the life sciences: exploring opportunities for European 
synergies. In this context, the participants proposed to establish a forum for the 
dialogue and coordination of funders, performers and decision makers, dedicated to 
setting future strategies in life science research. 
The following examples of projects supported under FP6 clearly illustrate that 
modern life sciences and biotechnology goes far beyond the technology of genetic 
modification or genetic engineering. 
•  Next generation toolbox for European genomic research 
The limitations of current technology – including cost and insufficient throughput 
and sensitivity – make it difficult to analyse genome variation between humans, or 
between different somatic cells within one individual. Such factors are vital in 
establishing the link between genetic profiles and diseases such as cancer. The new 
                                                 
8  http://europa.eu.int/comm/research/life-sciences/egls/index_en.html  
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generation micro arrays will, for example, be able to monitor genomes in action 
by measuring gene expression levels and correlating the resulting molecular profiles 
to a given disease state. 
A new technology-based research project “MolTools: advanced molecular tools for 
array-based analyses of genomes, transcriptomes, proteomes and cells”
9 
comprising 12 leading European academic groups, four biotech SMEs and one US 
laboratory, is expecting to produce a set of radically new array-based tools that will 
enable functional analyses of individual genomes and proteomes, right down to the 
level of single DNA, RNA and protein molecules within cells. 
An ERA NET project has been implemented under FP6: Trans European 
Cooperation and Coordination of Genome Sequencing and Functional Genomics 
of Human Pathogenic Microorganisms (PATHOGENOMICS, 11 partners, 8 
affiliated partners) with the main aim to harmonise the national pathogenomics 
programmes and to facilitate the research results exploitation. 
The array-based technologies making up the new ‘genomic toolbox’, will have an 
important impact on the development of diagnostic tools for clinical use. For this 
reason, the Commission has proposed that biotechnology research topics such as 
high throughput research, large scale data gathering and systems biology will be 
included amongst of the priorities in FP7 under the theme Health. 
•  Addressing the obesity epidemic and the burden of diet related diseases 
Research on obesity and nutrigenomics, the study of diet-gene interactions and their 
consequences for our health, is becoming an increasingly important area of research. 
The European Council of Ministers has expressed grave concern about the social and 
economic impact of the rise in the prevalence of obesity in Europe. In several 
countries, the cost of obesity is already representing 5% of total public health 
expenditure, largely due to the treatment of people suffering from high blood 
pressure, diabetes and high level of cholesterol in the blood. As a consequence of the 
rise in obesity, it is expected that by 2010, some 31 million Europeans will require 
treatment for diabetes
10. 
A number of EC funded projects under FP6 are bringing together a critical mass of 
complementary scientific competences in this area. 
–  Among others the projects “Diet, genomics and the metabolic syndrome (LIPGENE)”
11,” 
Diet, obesity and genes” (DIOGENES), European Nutrigenomics Organisation 
(NUGO)
12 aim to find out whether our genes modify the way diet affects our body. The 
project "Novel molecular targets for obesity and type 2 diabetes (DIABESITY)" brings 
together the leading researchers in Europe to find targets for intervening in the neuronal 
circuits that regulate body weight. Earlier research from project members has formed the 
basis for some of the most promising approaches for weight control currently in clinical trials. 
•  Genomics to advance animal health 
                                                 
9  http://europa.eu.int/comm/research/health/genomics/newsletter/issue3/newsletter1_en.htm 
10  http://www.idf.org/webdata/docs/CouncilConclusionsDiabetesMay2004.pdf 
11  www.lipgene.tcd.ie 
12 www.nugo.org  
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Improving the health of farm animals is a pressing issue. Diseases, in particular 
infectious diseases, not only cause very high economic losses (for example, a total 
loss of € 2.7 billion was recorded in several EU countries in 2001 as a result of the 
foot and mouth epidemic, but are a source of great public health concern due to the 
emergence of diseases transmitted from animals to humans (zoonotic diseases) such 
as West Nile, SARS, avian flu, BSE etc. In addition, therapies are becoming less 
effective as pathogens continue to develop resistance to them and there is an 
increasing pressure to cut down the use of drugs in order to reduce the risk that they 
enter the food chain. So, new control methods must be found to keep animals healthy 
and prevent diseases. Genomics offers new opportunities for controlling disease- for 
example by breeding genetic resistance into animals, developing new vaccines, and 
for rapid diagnosis. 
–  A number of projects funded under the thematic priority “ Food Quality and Safety” are 
addressing these issues such as the projects “European animal disease genomics 
network” (EADGENE)
13, “Prevention, control and management of prion diseases” 
(NeuroPrion) 
14, “Network for the prevention and control of zoonoses” ( MED-VET-
NET)
15, “Development of natural alternatives to anti-microbial for the control of pig 
health” (FEED FOR PIG HEALTH), “Control of the intestinal flora in poultry…” 
(POULTRYFLORGUT). 
– An  EC-US Workshop on “Emerging infectious diseases” organised in the context of the 
EC-US Task Force on Biotechnology Research, took place in June 2004. Two main 
recommendations emerged from the workshop: (1) the need to increase the understanding 
of the complex interactions of disease agents with wildlife and the environment and (2) the 
need for interdisciplinary research on emerging diseases, specifically human and veterinary 
medicine, but also the need to include other disciplines such as ecology, meteorology, 
bioinformatics, remote sensing, sociology etc 
– The  recently  launched  “European Technology Platform for Global Animal Health” which 
aims to facilitate and accelerate the development and distribution of the most effective tools 
for controlling animal diseases of major importance to Europe and the rest of the world, is 
expected to help speed up knowledge and product delivery and increase the collaboration at 
global level in this important area of research 
•  Plant genomics and biotechnology 
The Commission has continued its effort to promote research in Plant Genomics 
and Biotechnology at European level. 
                                                 
13  www.eadgene.org 
14 www.neuroprion.com 
15 www.medvetnet.org  
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•  In addition to the Integrated Project on improvement of grain legumes for food and feed 
(GRAIN LEGUMES)
 16 from 2003, a second Integrated Project entitled “Exploitation of 
natural plant biodiversity for the pesticide-free production of food” (BIOEXPLOIT) has 
been selected in 2004 for funding. This project will investigate the molecular components 
involved in durable disease resistance. It aims to develop, using genomics and post-
genomics tools, efficient and rational marker–assisted breeding and genetic engineering 
strategies to create disease resistant varieties. The project expects in particular to make 
substantial improvements in conventional breeding. It will focus on potato and wheat, the 
two most important staple crops for EU consumers, for which pesticides are indispensable 
at the moment. The impact of genomics research on classical breeding is still relatively low 
because there are no strong traditional strong links between breeders and genomics-
orientated researchers in the EU. The BIOEXPLOIT project will establish these links by 
bringing together breeders, geneticists, molecular biologists, plant pathologists, bio-
informaticians, economic interest groups, biotech companies and breeding companies into 
single project.  
–  The Commission efforts in this area have been strengthened by the launching of the 
Technology platform on Plants for the Future
17 in June 2004. 
The Commission efforts in this area have been strengthened by the launching of the 
Technology platform on Plants for the Future
18 in June 2004. 
•  Food and food safety 
The first generation of genetically modified crops focused primarily on improving 
agronomic traits for the benefit of the farmer, such as herbicide and pest resistance. 
The second generation is expected to try to improve food attributes such as 
nutritional value, colour, texture, flavour or processing properties. Foods, which 
might be genetically modified, in particular, are marketed by using claims of benefits 
to the consumers. Such claims can be broad, but the efficacy of the benefits and the 
inherent safety of the product must be demonstrated, in accordance with Community 
legislation. 
–  A STREP research project “NOFORISK”  will develop new quantitative risk-benefit 
assessment methods in particular to assess the safety and claimed benefits of food 
–  In the area of food safety, the Commission is also supporting 
– an  ERA-NET  “SAFEFOODERA” which will optimise and coordinate the funding of food 
safety research in Europe and strengthen the dialogue between consumers and producers. 
– an  IP  “SAFE FOODS” where new safety assessment methods are developed for foods 
produced by different breeding approaches and production practices, using modern profiling 
techniques, and new qualitative and quantitative risk-benefit (e.g. nutritional, economic). The 
three divergent food production systems are: (i) traditional high input agriculture, (ii) low input 
systems, including organic production and (iii) cultivation of genetically modified (GM) crops. 
•  Industrial Biotechnology 
Biotechnology’s best-known applications are currently in medicine and agriculture. 
However, it is already widely used in ecoefficient innovative industrial processes 
and products, where its long-term impact may be greatest.  
                                                 
16 www.eugrainlegumes.org 
17  http://www.epsoweb.org/Catalog/TP/index.htm 
18  http://www.epsoweb.org/Catalog/TP/index.htm  
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Industrial biotechnology refers to its use in manufacturing (chemicals, materials, 
energy) at every stage in the process, from supply of raw materials to end-of-pipe 
and clean-up. It is seen as a key technology for the sustainable development of 
societies worldwide. Biological processes offer the prospect of cheap and renewable 
resources, lower energy consumption and less waste products; zero greenhouse gas 
emissions, reduced dependence on (imported) petroleum and new markets for 
European agriculture. Examples of products already on the market include one of the 
most widely used fibrous polymers for household applications such as carpeting (du 
Pont’s Sorona
TM is now produced from corn using engineered biocatalysis rather than 
petrochemicals, a biodegradable plastic (PL A )  m a d e  f r o m  c o r n  i n  l a r g e  U S  b i o  
refineries, use of enzymes in the manufacture of chemicals ( this is a field in which 
European companies take a world lead), pulp and paper, food processing and mining 
and manufacture of some vitamins and antibiotics. Industrial biotechnology is 
expected to provide a smooth transition from a fossil-fuel-based economy to a bio-
based economy.  
Several Member States (e.g. UK, Belgium, Germany, The Netherlands, Sweden, 
France…) have launched their own initiatives and additional public–private 
partnerships on Industrial Biotechnology have been set up recently in the 
Netherlands and Belgium. US, Canada, and Japan have announced strong 
government and industry support. An international dialogue is also taking place at 
the level of the OECD.  
The recent report from the High Level Group headed by Wim Kok,
19 which carried 
out an independent review of the Lisbon Strategy, stresses among others the 
importance of stimulating eco-innovation, building leadership in eco-industry and 
pursuing policies which lead to long term and sustained improvements in 
productivity through eco-efficiency.  
The Commission recognising Industrial Biotechnology as an important eco-industry, 
has for its part, 
–  Supported the launch of the “Industrial Biotechnology Platform” as part of the a wider 
Sustainable Chemistry Technology Platform in order to boost this area in Europe; 
–  Proposed that Industrial Biotechnology becomes one of the priorities in FP7 under the theme 
“Food, Agriculture and Biotechnology”. It will form an important pillar of the “Knowledge 
Based Bioeconomy”. 
•  EC-US cooperation on plant based bio-products 
The Commission has initiated collaboration with the US in the context of the EC-US 
Task Force on Biotechnology Research, which brings together experts from plant 
and industrial biotechnology to identify areas of collaboration with respect to plant 
based bio-products. 
                                                 
19  http://europa.eu.int/growthandjobs/pdf/2004-1866-EN-complet.pdf  
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–  EC-US cooperation in plant based Bio- Products Research 
–  An EC-US workshop on “Applications of molecular biology to enhance plants for the 
purpose of producing bio based products and bio energy”
20, supported by the EC-US 
Task Force on Biotechnology Research, took place in Albany, California, in April 2004. A 
joint working group
21 was established to further facilitate and coordinate collaborative (EU-
US) research in this field. The working group has developed a strategy paper “Plant-Based 
Bioproducts: Creating value from renewable biological resources”
22 to underpin and 
direct a new vision for US-EU collaboration in agricultural and industrial biotechnology. In 
addition, the working group has initiated the development of two flagship projects
23: Plant cell 
walls: raw material quality and utility for biorefining
24 and Oilseed Engineering
25. 
•  Nanotechnologies – Nano-biotechnology  
Nanosciences and nanotechnology are important for underpinning the advances in 
life sciences and biotechnology. The convergence of inorganic nanotechnology and 
biotechnology into nano-biotechnology has the potential to yield breakthrough 
advances in medical diagnosis, targeted drug delivery, regenerative medicine and 
chemicals screening. 
An integrated and responsible approach to nanotechnology lies at the heart of the 
Commission’s Communication “Towards a European Strategy for 
Nanotechnology”
26 adopted on 12 May 2004. Actions in a range of areas were 
highlighted: research and development; infrastructure; human resources; industrial 
innovation; societal issues, public health, safety and consumer protection; and 
international cooperation. It was also highlighted that synergy with the European 
Strategy on Life Sciences and Biotechnology may be beneficial. 
The Communication was welcomed by the Council on 24 September 2004
27. The 
European Economic and Social Committee also issued a favourable opinion on the 
Communication on 10 November 2004
28. An open consultation then was conducted 
that received 750 responses from a wide range of stakeholders
29. Taking into account 
the outcome of that consultation, on 7th June 2005, the Commission adopted the 
Action Plan "Nanosciences and nanotechnologies: An action plan for Europe 
2005-2009"
30. This Action Plan defines a series of articulated and interconnected 
actions for the immediate implementation of a safe, integrated and responsible 
                                                 
20  http://www.pw.usda.gov/wrrcpagedoc/euus/US-%20EC%20Proceedings.pdf 
21  The steering committee is composed of representatives from the European Commission, University of York, 
National Hellenic Research Foundation and Agricultural Research Service of the U.S. Department of Agriculture. It 
is envisioned that a wider advisory network of specialists and stakeholders will support and take part in the 
committee 
22  http://www.pw.usda.gov/wrrcpagedoc/euus/Draft%20Strategic%20Vision%20pa%201.htm  
23  Flagship projects address complex technological challenges and are to contribute to solving a major socio-
economic problem. They require the demonstration of strong benefits, in particular for consumers and the 
environment and should also be in line with other important policy priorities of both the EU and USA. They build 
on the respective strengths and complementarities of the European and US scientific and technological knowledge 
base and industries. 
24  http://www.pw.usda.gov/wrrcpagedoc/euus/ANNEX%20I%201.htm  
25  http://www.pw.usda.gov/wrrcpagedoc/euus/OilseedFlagship%201.htm  
26  Towards a European Strategy for Nanotechnology COM(2004) 338 
27  Conclusions of the Competitiveness Council, Brussels 24 September 2004 12487/04 p.24-26 
28  Opinion to be published on http://www.esc.eu.int/  
29 See  http://www.nanoforum.org/dateien/temp/nanosurvey6.pdf?20122004094532  
30 COM(2005)  243  
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strategy for nanosciences and nanotechnologies, based on the priority areas identified 
in the above-mentioned Communication. 
•  NanoMedicine is an emerging area with high potential for growth and employment 
with the ultimate target of improving quality of life. Already now not only large 
companies but a high number of SMEs are active in this field which nevertheless is 
quite fragmented. Therefore, stakeholders expressed the need for a European 
Technology Platform in this area to build a sound basis for competitiveness in 
NanoMedicine. A multidisciplinary and highly motivated group of stakeholders with 
many industrial companies in the area of NanoMedicine prepared a vision 
document that will be ready in summer 2005. The priority areas chosen by the 
stakeholders group are 1) nanodiagnostics including medical imaging 2) 
targeted drug delivery and release and 3) regenerative medicine. The 
European Platform on NanoMedicine will be launched officially on 6th September 
2005 with immediate creation of working groups to set up the strategic research 
agenda. 
•  A network of excellence “NANO2LIFE”, already funded under FP6, provides an interface 
between nano- and biotechnology, between public and private sectors, and between 
academia, industry and hospitals. The intention is to build an EU community that shares 
research, training and tools as well as foresight analysis. 
•  In April 2004, the Commission organised a workshop to discuss the current situation and 
future developments and applications of nanobiotechnology in the health sector.  
•  The workshop served to design the prospective study “Nanobiotechnology in the medical 
sector – drivers for development and possible impacts”, which was launched January 
2005. The study aims to draw a comprehensive picture of the R&D and commercial medical 
nanobiotechnology landscape in Europe in comparison to the US and Japan. Furthermore, 
the impact and likely development of nanobiotechnology applications in the medical sector 
will be investigated and the socio-economic aspects of this development analysed. 
Nearly every European Member State has nanotechnology research funding 
initiatives, including activities covering medical applications.  
•  A recent study carried out for the German Federal Ministry for Research and 
Education in the context of a broad nanotechnology analysis
31, investigates 
chances and challenges of nanotechnology applications in the medical sector. 
Within the next ten years major developments are expected. According to the 
study, highly selective diagnostics and therapeutics based on nanotechnology have 
the highest economic potential but also applications that support homecare and 
telemedicine 
•  In May 2004, the French Senate published a report on nanoscience and medical 
progress
32. The report discusses the economic issues regarding nanobiotechnology 
both in France, other member states and non-European countries. It includes 
several recommendations on studies that should be carried out: one regarding 
possible nanotechnological impacts on the environment and health, one related to 
the toxicity of nanoparticles, and one study related to the cost of the growing use 
of nanobiotechnology. The report also proposes an interdepartmental programme 
                                                 
31  Farkas, R. et al., Nanotechnologie pro Gesundheit: Chancen und Risiken, 2003 . http://www.bmbf.de/1324.php 
32  Lorrain J.M. and Raoul D., (2004), Rapport sur Nanosciences et progress medical, Bureau de l'Assemblée nationale 
and Bureau du Sénat, http://www.senat.fr/rap/r03-293/r03-2931.pdf  
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(NanoTech or the French NNI) with the objective to integrate industry and 
academia to attract private funding for research 
•  In July 2004 The UK Royal Society published its report on “Nanoscience and 
nanotechnologies: opportunities and uncertainties”
33. It provides an overview of 
the state-of-the-art including nanobiotechnology and analyses potential risks and 
regulatory issues arising with the applications of nanotechnology. The main area 
of concern identified in the study related to production and use of nanoparticles. It 
is recommended to review regulation accordingly, including regulation on 
medicines and medical devices. The UK Government also issued a national 
agenda on nanotechnology earlier this year. The Government stresses the need for 
a precautionary approach and invites a public debate at an early stage. DEFRA 
has been given a co-ordinating role as regards the risk analysis and preventive 
measures. 
•  In October 2004, a call for the establishment of new “Laboratórios Associados” 
was launched in Portugal. The status of “Associated Laboratory” is attributed to 
institutions of high merit recognised from external assessments following 
application made by the institution and based on its capacity to cooperate in a 
stable, competent and efficient manner in the pursuit of specific national scientific 
and technological objectives. The call’s priority areas include biotechnology and 
nanosciences-nanomaterials. 
The European Science Foundation (ESF) recently carried out a foresight activity 
on nanomedicine (“Forward Look on Nanomedicine”). The initiative aimed at 
reviewing the state-of-the-art in Nanomedicine, and identifying future trends in the 
next decade. Points discussed were diagnostic tools, nanomaterials and nanodevices, 
and drug development and delivery. The preliminary version of the report is expected 
to be completed in 2005
34.  
•  Small & Medium Enterprises (SME) 
The 6th Framework Programme for Research has also continued to attract industry 
and in particular SME’s. 
In the Health Research Priority 12% of all participating partners in projects funded in 
the first call are SMEs (representing around 10 % of the budget). 95% of the funded 
Integrated Projects in the first call includes one or more SMEs. More than 90 % of 
these are research intensive SMEs, and the remaining SMEs contributes with 
expertise in project management, communications, etc. As expected, the area 
“Application of knowledge and technologies in the field of genomics and 
biotechnology for health attracted the highest number of industrial partners within 
Health Research Priority. In this area, 23 % of the partners funded following the 1st 
call are from industry (of which 83 % are from SME) and 16.3 % of the budget was 
allocated to industry of which 90 % was attributed to SMEs. Further efforts have 
been made to increase the participation of SMEs. In the 2nd call around 14 % of 
participating organizations are SMEs (representing around 9 % of the budget). In the 
                                                 
33  The Royal Society: “Nanosciences and nanotechnologies: opportunities and uncertainties”, 2004, 
http://www.royalsoc.ac.uk/landing.asp?id=1210 
34 http://www.esf.org/publication/196/ESPB23.pdf  
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3rd call 15.1% of the estimated budget (the projects are still under negotiation) was 
allocated to SMEs (for all types of proposals retained for funding) and 18.2% of 
partners being SMEs. In this call a high number of research topics of specific interest 
to SMEs were introduced, and in connection with the 4th call there will be a specific 
part dedicated to SME-STREPS (Science and Technology Research Projects) with an 
indicative budget €171 million.  
Under the thematic priority “ Food Quality and Safety “ the ratio of SMEs 
participating in funded projects has increased significantly from 12.5% under the 1st 
call for proposals to 20.2% in the 2nd call and 12.6% of the budget was allocated to 
SME’s 
In addition to the participation in the activities implemented under the priority 
thematic areas, two specific schemes for SMEs having a potential to innovate but 
with limited research capacity have been implemented. Within these schemes, SMEs 
or groupings dominated by SMEs may entrust research work to solve their particular 
problems to research performers (research institutes, universities etc.) So far about 
23% of the budget allocated to these specific activities for SME’s has been attributed 
to research in the field of Life Sciences and Biotechnology. As an example, the co-
operative research project MICROBEARRAY, which intends to carry out a genome 
scale analysis of the immune response against a variety of pathogenic micro-
organisms thus filling the gap between genomic data and development of novel 
vaccines and diagnostic tools. Furthermore, an ERA-NET “European network of 
transnational collaborative RTD for SMEs in the field of biotechnology” 
(EUROTRANSBIO) was funded, to develop best practices and establish cross-
border partnerships between SMEs and /or public research laboratories working in 
the field of biotechnology. A large number of initiatives have also been financed 
under FP6 to encourage and facilitate SMEs and SME groupings participation and 
exploitation of the research supported in FP6. 
A number of projects funded under the thematic priority: Life sciences, genomics and 
biotechnology for health are addressing these issues, such as the projects Training 
Programme for Future Bioentrepreneurs (BIOBIZ 4), Biotech Venture 
Academy Coaching Programme for NAS Biotech Companies Seeking to Raise 
Investment (BIO VENTURE EAST). 
Actions to support research for SMEs carried out by universities and research centres 
will be scaled up significantly in FP7.  
The Research Framework Programme and the Competitiveness and Innovation 
Framework Programme (CIP) will operate side by side, and with considerable cross-
over, in support of the Lisbon goals. The CIP programme will, for example, support 
networks that help SMEs to participate in the Research Framework Programme, and 
fund a Business Innovation Support Scheme as well as a new High Growth and 
Innovative SME facility aiming at reducing the equity market gap which prevents 
SMEs from exploiting research results.  
The Commission has proposed a substantial simplification and rationalisation of the 
way the 7th Framework Programme will work and it is hoped that these measures 
will facilitate the participation of SMEs in the programme.  
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•  Infrastructures 
Six new projects for Research Infrastructures in Life Sciences and 
Biotechnology have been awarded an EU contribution of € 10.3 million in 2004. 
The projects will participate in structuring the European Research Area, by 
supporting European access to a technology infrastructure on neural computation, by 
coordinating European infrastructures in the domain of protein crystallography, by 
designing European databases in the fields of glycomics and human development and 
by supporting the construction of new European infrastructures in the fields of 
structural biology and highly contagious diseases. 
The Council of Ministers in its meetings of 1-3 July and 25-26 November 2004 
proposed to develop a strategic roadmap for new Research Infrastructures in 
Europe over the next 10 to 20 years. The European Strategy Forum for Research 
Infrastructures (ESFRI) is now preparing a roadmap that will in particular cover 
"Biological and Medical Sciences”. A first list is expected to be presented to the 
Commission in 2005. 
The Commission has started an exercise for mapping existing Research 
Infrastructures in Europe. This will provide an up-to-date picture about the current 
pattern, and will help in understanding the needs for future Research Infrastructures. 
The whole range of scientific and technological fields is covered by the survey, 
including Life Sciences and Biotechnology. The results of the survey will be made 
public in the second half of 2005.  
•  Technology Platforms 
The establishment of technology platforms
35, an innovation in EU research policy, 
have continued to develop and foster public-private partnerships at European level. 
They represent a mobilising force by bringing together all relevant stakeholders in a 
given sector to develop a strategic, long-term research agenda and to implement the 
research agenda through public and private investments at European, national and 
regional level. They are expected to contribute to the effort to boost research and 
technological development in Europe and to leverage knowledge for economic 
growth and competitiveness. Industry’s lead role in the platforms is crucial in this 
regard. The industrial leadership of platforms ensures that they are focussed on 
potential future markets for key technologies. This leadership can provide the 
necessary impulse to realise Europe’s potential in leading-edge technologies and help 
to build the capacity to transform scientific excellence into commercial success and 
economic growth. It can also stimulate the emergence of first-mover markets in 
Europe. They provide a framework for industry, scientific and financial worlds to 
come together and make viable projects that can only be conceived at European 
level. This in turn will boosts research performance and investments.  
A number of technology platforms in life sciences and biotechnology have now been 
launched. 
                                                 
35  http://www.cordis.lu/technology-platforms/home.html  
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– The  Technology platform on Plants for the Future
36 was officially launched in June 2004 
and a vision paper was made public at the same time. A broader stakeholder involvement to 
is foreseen for the development and deployment of the strategic research agenda, which is 
expected to be available for discussion and consultation in 2005. The platform focus is on 
improving the sustainable use of plants to produce healthy, affordable and diverse food and 
feed, biomaterials and bioenergy, making use of modern biotechnology 
–  The European Platform on Innovative Medicines for Europe37 was established during 2004. 
A vision paper was prepared in December 2004. The objective is to remove bottlenecks 
hampering the efficiency of the development of new medicines, and where research is the 
key to resolve current obstacles for the European pharma/biotechnology industry to become 
world leaders. The strategic research agenda identifying critical scientific gaps in which more 
pre-competitive research is urgently required is developed together with relevant 
stakeholders. Specific areas to be addressed by the platform are the improvement of 
methods for prediction of safety and efficacy of new drugs, improved knowledge 
management across disciplines involved in the drug development process, improved mobility 
of researchers between disciplines as well as education and training aspects. 
–  Industrial Biotechnology Platform
38 is one of the three pillars of the Sustainable Chemistry 
Technology Platform, which was set up in June 2004. It has organised two stakeholder 
events. A vision paper has been finalised in April 2005 following discussion with relevant 
industrial sectors, consumers and NGOs. A working group has been set up to develop the 
Strategic Research Agenda. The focus is on the application of biotechnology for sustainable 
and eco-efficient production of chemicals, materials and bioenergy. Industrial biotechnology 
use living cells and/ or their enzymes to transform renewable feedstock (e.g. starch) into 
such products. 
– The  European Technology Platform for Global Animal Health
39  was launched on 16 
December 2004. The objective is to facilitate and accelerate the development and 
distribution of the most effective tools (vaccines, diagnostics…) for controlling animal 
diseases of major importance to Europe and to the rest of the world. An interim vision paper 
was prepared by a high level group.  
Other technology platforms are under preparation and are expected to be launched in 
2005 including European Technology Platforms on NanoMedicine
40, Food for Life
41, 
Forestry- based sector 
42 and Farm animal breeding
43. 
The technology platforms are expected to play an important role in the transition 
from FP6 to FP7. In fact, it is proposed that FP7 should have more focus than in the 
past on developing research that responds to the needs of European industry, through 
the work of Technology Platforms and the new “Joint Technology Initiatives”. The 
definition of work programmes should draw on the strategic research agendas 
developed by the industry-led technology platforms. The new “Joint Technology 
Initiatives” will be projects in fields of major European public interest on subjects 
identified through dialogue with industry, in particular in the European Technology 
Platforms. 
B) The Seventh Framework Programme 
                                                 
36  http://www.epsoweb.org/Catalog/TP/index.htm 
37  http://europa.eu.int:8082/comm/research/fp6/p1/innovative-medicines/index_en.html 
38 http://www.europabio.org/sustainable_chemistry_platform.htm 
39 http://europa.eu.int/comm/research/agriculture/pdf/etpgah_vision2015_paper-final_en.pdf 
40 www.cordis.lu/nanotechnology/src/nanomedicine.htm 
41 http://www.ciaa.be 
42 http://www.forestplatform 
43 http://www.faip.info/  
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On 6 April the Commission adopted a proposal for  the  EU Seventh Research 
Framework Programme 2007-2013 (FP7)
44. Subtitled “Building the European 
research area of knowledge for growth”, FP7 is designed to provide new impetus to 
increase Europe’s growth and competitiveness, recognising that knowledge is 
Europe’s greatest resource. The Commission proposes in particular to double the FP7 
budget compared with FP6. 
Life Sciences and biotechnology research for medical applications will remain an 
important priority under the theme “Health” (including healthcare technologies, 
medical technology and pharmaceutical industries). But FP7 is also expected to give 
a major impetus to food, agriculture, marine, industrial and environmental 
biotechnology under the theme “Agriculture, food and Biotechnology”. It is the 
intention of the Commission to bring together the relevant technologies and sectors 
to develop a European Knowledge Based Bio-Economy
45, which will provide the 
necessary critical mass, synergies, and outputs to meet social and economic demands 
for the sustainable and eco-efficient production and utilisation of renewable 
biological resources and their transformation into health, food, energy and other 
industrial products which can provide an incentive for increased growth and 
employment. A conference “Towards a knowledge based bio- economy in 
Europe”,  addressing these aspects,  will take place 15-16 September 2005. The 
conference will bring together policy makers and civil servants (research policy 
makers at EU and national level), representatives from research funding bodies, 
industrial managers, civil society representative groups, learned societies etc. It is 
hoped that this conference will be the start of a European debate on the challenges of 
a Knowledge Based Bio-Economy. 
As a follow-up of this conference the Commission intends to establish a network of 
officials from across Europe in order to stimulate a coordinated effort in the 
development and implementation of a research and innovation policy for a 
knowledge based bio-economy. This work will be carried out in coordination with 
the Standing Committee on Agricultural Research (SCAR) and other existing 
Biotechnology Networks. The Commission will  report on the outcome of 
this coordination. 
FP7 will establish for the first time a “European Research Council” (ERC), funding 
the best of European science, as assessed by peer review of European scientists. This 
will be the first time that a body like this has existed at European level, identifying 
the very best of European research wherever and however it is carried out. As the 
ERC will be open to any scientific discipline it will also provide the opportunity to 
identify new scientific ideas and areas in the field of Life Sciences, which could be 
taken up elsewhere for further action and promotion. 
Another new element will be the development of “regions of knowledge”, bringing 
together research partners – such as universities, research centres, enterprises and 
regional authorities - in a region to strengthen their research potential. 
                                                 
44  COM(2005) 119 final 
45  We understand the term “bio-economy” as including all industries and economic sectors that produce, manage and 
otherwise exploit biological resources (such as ,agriculture, food, forestry, fisheries, health ) and related services, 
supply or consumer industries.  
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1.1.2.2.  Exploitation of intellectual property 
A) Intellectual property protection 
After receiving the opinion of the European Parliament, the Commission proposal for 
a Regulation on the Community Patent
46 is being discussed in the Council, where, on 
3 March 2003, a common political approach was agreed on a number of issues.  
Following this there was significant progress in the Council in incorporating the 
common political approach in the text of the Community Patent Regulation and the 
text was practically finalised in November 2003. However, since then the Council 
has repeatedly failed to reach final agreement. In the meanwhile, the Commission 
has on 23 December 2003 presented proposals for Council decisions on the setting 
up of the Community patent jurisdiction
47 . The Economic and Social Committee 
has issued its overall very positive opinion on 31 March 2004
48 and the European 
Court of Justice has delivered its opinion on these proposals on 29 October 2004
49. 
To date, twenty Member States
50 have transposed Directive 98/44/EC
51 on the legal 
protection of biotechnological inventions into their national legal systems while the 
other Member States are currently at varying stages of progress.  
On 9 July 2003, the Commission referred eight Member States to the European Court 
of Justice for their failure to transpose the Directive into national legislation. Among 
those, three infringement procedures are still pending
52. In December 2004, two 
other infraction procedures were launched against Latvia and Lithuania. 
For its part, in its second report pursuant to Article 16c of the Directive, the 
Commission has considered two questions identified in the Annual Report of the 
Commission to the European Parliament and the Council on the development and 
implications of patent law in the field of biotechnology and genetic engineering 
provided for by Article 16(c) of Directive 98/44/EC
53, namely the scope of patents 
relating to sequences or part-sequences of genes isolated from the human body, and 
the patentability of human stem cells and cell lines obtained from them. The 
Commission analysis takes into account the contribution made by its informal group 
of independent experts set up for advising the Commission on the preparation of 16c 
reports. 
The Commission is also working on the first report provided for in Article 16a on 
any problems encountered with regard to the relationship between the directive and 
international agreements on the protection of human rights to which the Member 
States have acceded. Its adoption is scheduled for October 2005. 
                                                 
46 COM(2000)412   
47  COM (2003) 827 and COM (2003) 828 
48  OJ 2004, C 112/76 and C 112/81 
49  Council document n° 14349/04 
50  Denmark, Finland, Ireland, United Kingdom, Greece, Spain, Portugal, Sweden, the Netherlands, France, Germany, 
Belgium, Estonia, Czech Republic, Slovakia, Cyprus, Poland, Hungary, Malta and Slovenia. 
51  OJ L 213, 30.7.1998, p.13. 
52  Luxembourg, Austria and Italy. 
53 COM(2002)545    
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B) Improve understanding within academic community on how to turn applied 
research into innovative products 
An expert group of technology transfer and legal specialists has finalised in 2004 
a report on “Management of Intellectual Property in publicly funded research 
organisations – towards European Guidelines”
54 and a "Handbook on responsible 
partnering" developed by four European associations (with Commission support), in 
order to facilitate university-industry R&D collaborations and technology transfer 
has been published
55. CREST made a number of recommendations in October 
2004
56, which also relate to university-industry relations and technology transfer. 
A Commission study providing a detailed comparative analysis of the Intellectual 
Property Research (IPR) rules applicable to publicly-funded research, their 
evolution and their effects, in the 15 EU Member States, in 2 adhesion countries, as 
well as in the US and Japan will be launched by end of 2005. The study will focus on 
legislative aspects and gives recommendations in order to improve the coherence of 
the IPR regimes applicable to publicly funded research in the European Union.  
The Commission is also financing under FP6, the following projects 
–  The patenting of human DNA: Global trends in commercial and public sector activity 
(PATGEN)  which  will provide an evidence-based analysis of the dynamics of patent 
applications and grants claiming human DNA sequences and will analyse the data for 
determination of patent grants rate made to the EPO, the fate of patents not granted and the 
ways in which granted DNA patent are being exploited. This information will be reviewed and 
interpreted in light of current national and EU policies for IP in biotechnology. The results will 
be available end 2005/beginning 2006; 
–  Stem Cell Patents: European Patent Law and Ethics (Stem Cell Patents) –launched in 
2005, aims to provide an analysis of the EU patent system, as applied to biotechnological 
invention in general and to embryonic stem cell related technology in particular, with a view 
to ascertaining the legal effect of ethical or legal divergence on European patent laws. 
Member States and the Commission are actively participating in an OECD exercise 
to develop licensing guidelines for genetic inventions, in particular as regards 
access for research purposes and genetic testing in public health care. Draft 
guidelines will be available early 2005. 
In Denmark, a national network for technology transfer has been established with the 
aim of promoting professionalism in the management of IP and commercialisation of 
inventions from public research by training of tech trans officers and R&D-
managers. The Danish Tech Trans Network also activated a web-site
57 offering an 
overview of IPRs and access to tech trans contact- points and policies from all public 
research institutions. The network was assigned a government grant of €2 million for 
the period 2005-2008. 
C) Capital base 
                                                 
54  http://europa.eu.int/comm/research/era/pdf/iprmanagementguidelines-report.pdf 
55 see  http://www.eirma.asso.fr/f3/local_links.php?action=jump&id=796 
56 see  http://europa.eu.int/comm/research/era/3pct/pdf/crest-conclusions_en.pdf, in particular recommendations 11-18 
57 www.techtrans.dk  
EN  21     EN 
The Commission has adopted a proposal for a Competitiveness and Innovation 
Program
58 with a total budget of 4.2 billion € for 2007-2013. It is designed to provide 
instruments to develop and sustain a supportive environment for innovative firms, 
encouraging clusters, and strengthening access to finance by new elements (e.g. a 
risk capital instrument for High Growth and Innovative Companies and 
securitisation” of banks’ SME loan portfolios). 
Providing access to capital seems to be particularly relevant at this stage since the 
global economic slowdown and the burst of the high-tech bubble in equity markets 
have hit the biotech industry particularly hard. The drop in price/earnings ratios and 
the fall in high-tech indices like the NASDAQ Biotech Index provide a clear 
indicator for the increased difficulties biotech SMEs and even established companies 
have in this sector to get access to capital. 
The Commission has in collaboration with European Investment funds (EIF) 
launched a feasibility study in June 2004 on a new type of risk capital and 
technology transfer investment vehicle, the “Technology Transfer Accelerator”, 
which aims to link different centres of excellence and universities in European 
countries. This instrument should bridge the finance gap between university/spin-off 
research and early stage investment, a sector currently not favoured by VC investors. 
The result of the study on a possible “Technology Transfer Accelerator” instrument 
should be available by mid 2005. The Commission is also financing 
entrepreneurship training courses with particular focus on scientists in the New 
Member States.  
The Biotech and Finance Forum (BFF) Advisory Board, including all relevant 
biotech stakeholders in Europe, as well as representatives of major bio-clusters, 
venture capital firms, consultants, etc. in the biotech sector,  will among others 
address the creation of a better investment climate for industrial and plant 
biotechnology. A first round table bringing together industry, small companies and 
investors in the area of industrial biotechnology was organised just following the 
BFF conference in Barcelona in November 2004. 
The Commission, within its proposal for the 7
th R&D Framework Programme (FP7), 
has outlined a new financing instrument, the “risk-sharing finance facility”, which 
could provide loans for larger research and infrastructure projects. This instrument, 
relying on an existing facility of the EIB and managed by the EIB, could provide 
finance for research in high technology areas by private companies and institutions, 
for which the risk cannot properly be assessed by classical banks and are therefore 
considered too risky. FP7 funds will be used in addition to EIB and as a reserve to 
cover the risk associated with the EIB lending operation, thereby providing a 
leverage effect (factor of 3-4). This instrument can be in particular useful for 
financing high-risk biotech R&D drug development projects, large scale 
collaborative research projects (technology initiatives, Eureka projects) or for new 
research infrastructures. 
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1.2.  NETWORKING EUROPE’S BIOTECHNOLOGY COMMUNITIES  
Fragmentation remains a crucial issue for Europe’s biotechnology stakeholders. 
There is still too little cross-national collaboration between researchers and 
companies, and too little awareness of developments in other European countries. 
There are many regional biotechnology clusters, although co-operation between them 
is under-developed; this is a particular problem considering that many of them lack 
critical mass. 
In consequence, networking is vital for the effective further development of 
biotechnology in Europe. 
Several initiatives supporting networks in Europe are on-going. 
•  The Commission is supporting the creation of a commercial biotechnology web 
portal for Europe that will help free access to information and networking 
available Internet platforms. The tender process was completed and the contract 
awarded in 2003. However, subsequent delays related to co-funding have led to 
the project now being some two years behind the originally-envisaged schedule. 
Work was held up due to a delay in the availability of expected co-funding. The 
co-funding issue has been addressed by putting the project on hold until the 
required funding from the French authorities becomes available. Work is expected 
to resume in spring/summer 2005 with completion likely in late-2005. 
•  Stronger cross-border and interregional co-operation in the life sciences and 
biotechnology area is developing in a number of European regions. These 
activities, such as interregional networks, can be considered eligible for financing 
under the INTERREG III initiative. The INTERREG III ber programs (strands 
A, B and C) are operational in all 25 Member States. In particular the INTERREG 
III C program launched two calls for proposal projects in 2004
59. 
•  The Commission, through the 6th Research Framework Programme, has funded a 
number of specific support actions aiming at increasing networking between 
European bioregions and clusters. An example is the project “ScanBalt 
Competence Region”, a model case to enhance European competitiveness in life 
sciences, genomics and biotechnology for health on a global scale”. It aims to map 
the competence in the member regions of the ScanBalt network and jointly design 
a development strategy for this region and the ScanBalt IP knowledge network is 
a project aiming at developing a sustainable intellectual infrastructure that can 
increase the creation of value from bioscience research.  
•  A larger workshop bringing together about 100 representatives of European 
bioregions took place in the Bio-Vision 2005 conference in April in Lyon. At a 
workshop of the Bio-Vision 2005 conference a new meta-region network 
“EuroBioClusterSouth” was launched, bringing together bioregions from Spain, 
France, Germany, Switzerland and Italy. 
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•  The Commission has also organised a workshop in Basel in March 2004 bringing 
together over 40 representatives of bioregions, clusters and incubators to discuss 
the way forward to increased networking of bioregions in Europe. In a follow-up 
meeting in June 2004, a proposal for establishing a formal network of bioregions 
from across Europe was made, for which start-up financing is currently being 
sought. This pan-European network of bioregions should identify a joint strategy, 
including structures for supporting research collaboration, networking and joint 
actions, to strengthen the economic development of European Biotechnology. A 
second preparatory meeting is planned for mid 2005. 
1.3.  A PROACTIVE ROLE FOR PUBLIC AUTHORITIES  
1.3.1.  The Contact network 
In 2004, all Member States from EU15 except for Greece were part of the contact 
network with national ministries with responsibilities for competitiveness in 
biotechnology  set up by the Commission. New Member States - Lithuania and 
Slovakia - have also joined. Contact points in almost all other Member States have 
been established. For these, official appointments should take place in 2005. The 
network has met regularly in 2004. Relevant contributions to the study on 
benchmarking of public biotechnology policy have been made. 
1.3.2.  The Competitiveness in Biotechnology Advisory Group 
In accordance with Action 10b of the Strategy, in 2003 the Commission appointed a 
Competitiveness in Biotechnology Advisory Group with Industry and Academia 
(CBAG). It gathers representatives from all the various industry segments and from 
companies at every stage of company development together with entrepreneurial 
academics and has the role of issuing recommendations to the Commission and 
contributing to this annual report. 
The CBAG’s 2004 Report provided 10 “key recommendations”, which were in effect 
policy statements regarding various aspects of biotechnology strategy
60. It also 
specified a larger number of detailed actions, focusing on the policy areas of 
Financial Opportunities, Issues & Obstacles and Regulatory Issues & Requirements. 
1.3.3.  The guide to Community regulation 
The contract for a guide to Community regulation for users and for entrepreneurs has 
been awarded in 2004 and drafting of the guide will be finalised by end 2005. It will 
then published on the Commission’s biotechnology web-pages and regularly 
updated. 
1.3.4.  The benchmarking study 
The study on benchmarking of public biotech policy aimed primarily at providing 
European policy-makers with a set of tools that will assist them in their policy-
making regarding biotechnology. The contents of the benchmarking study of public 
biotechnology policy were agreed beginning 2004. The project-team directed most 
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efforts at putting in place the right methodology. Analysis of the first round of 
benchmarking has allowed identifying the benefits as well as the limitations
61 of the 
tool-box. For this, suitability of the methodology should be verified in future 
exercises. The general objective of the project is to identify public policies that affect 
the development of biotech in Europe and assess their effectiveness against a 
background of verifiable data. Final report was delivered in mid-March 2005
62. 
The report will be published, and its results be used for policy discussion with 
member states and industry. Commission and Member States will proceed to a new 
round of benchmarking in 2006/7.  
2.  GOVERNING LIFE SCIENCES AND BIOTECHNOLOGY 
2.1.  SOCIAL SCRUTINY AND DIALOGUE  
A continuation of the effort made by the European Union – and its Member States – 
in recent years to draw together the ‘innovation triangle’: science, society and the 
economy remains a priority. The Science in Society Forum 2005
63 organised by the 
Commission on 9-11 March 2005 reviewed these efforts and helped to plot a new 
course forward in the field of Science in Society. The conference reviewed a number 
of national and EU experience on citizens' participation in science deliberations and 
public debated on issues linked to life sciences and biotechnology. A series of 
national mirror events helped setting the tone and agenda for the Forum.  
Biotechnology, in particular in agriculture and food, is still not well-received by the 
general public. Recent public perceptions analysis clearly suggests that consumers’ 
reluctance towards GMOs is caused not so much by perceived risks rather than lack 
of perceived benefits
64. The Commission has developed a number of activities in the 
field of governance, notably regarding the participation of civil society to decision 
making processes, the collection and use of expertise and scientific advice: 
–  The project “Impact of Scientific Advice on Risk Communication” is examining the issue 
of risk communication with the general public through the printed media and will analyse the 
flow of risk related scientific advice between the main actors involved (scientists, policy 
makers and civil society). This will be illustrated by two case studies on GMOs and SARS. 
The final report will be available in 2005.  
–  The European Risk Communication Network project will develop a reference book, 
guidelines and training material that can guide in the communication among the various 
actors and reinforce the links between them including presentation and discussion of basic 
risk concepts and EU policies in schools, science museums and settings fostering public 
participation and involvement 
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64  Gaskell, G., Allum, N., Wagner, W., Kronberger, N., Torgensen, H., and Bardes, J. (2004). GM foods and the 
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–  The project “Participatory Approaches in Science and Technology” (PATH) will form a 
network bringing together academics, practitioners, policy-makers and stakeholders to 
exchange knowledge and develop future directions for the involvement of society in the 
deliberation of science-based policy issues. The two cross-cutting themes of representation 
and scale will be explored at a generic level, and via three case study areas: genetically 
modified organisms (GMOs) in agriculture, biodiversity conservation and nanotechnology 
–  The  Deliberative Citizens’ Debates in European Centres and Museums project 
(DECIDE) aims to raise awareness and understanding of deliberative democracy methods, 
produce a tool to conduct and facilitate face-to-face and on-line deliberative consultations 
and monitor the change of attitudes among the European public on Life Sciences. DECIDE 
will produce a “kit” to facilitate structured debates on controversial issues (notably stem cells, 
cloning, GMO, genetic and property rights etc.) in many science centres and museums 
across Europe 
– A  European Multimedia Repository on Life Sciences will produce short films on topical 
life science issues. The films will be made available through TV, internet and by 
VHS/DVD/CD ROM. In addition the proposal will also provide a rapid response science 
network where scientists will answer questions related to topics addressed in the films 
The Commission has also supported a number of conferences in 2004. In particular, 
the  3
rd Science Generation Symposium “Biotechnologies: possibilities, risks, 
ethics and society” took place in Stockholm in August 2004, as a satellite of the 
EuroScience Forum. It gathered hundreds of EU students, teachers and parents to 
discuss with science experts and policy makers on genetically modified crops and 
genetic integrity. The Encounter “Modern Biology and Visions of Humanity”, 
organised under the aegis of the European Group on Life Sciences (EGLS) in Genoa 
in March 2004, gathered scientists and thinkers from the humanities and the arts to 
reflect on the impact of life sciences on our representations of humanity and nature
65. 
The Commission  will launch a Eurobarometer survey specifically focussed on 
biotechnology in the latter part of 2005 as the next in a series, which was started in 
1991. Interestingly, the April 2005 Special Eurobarometer on “The Attitudes of 
European Citizens towards Environment”
66 showed that the use of genetically 
modified organisms in farming is not among the environmental issues that worry the 
Europeans most. 24% of the respondents mentioned it as an issue of concern, the 
topic being the 10th most mentioned topic out of 15. However, the topic stands out as 
the 2nd most often mentioned issue for which Europeans feel they lack information, 
environmental protection associations and scientist being the most trusted sources of 
information. 
2.2.  DEVELOPING LIFE SCIENCES AND BIOTECHNOLOGY IN HARMONY WITH ETHICAL 
VALUES AND SOCIETAL GOALS  
2.2.1.  Community support for research into socio-economic and ethical issues 
Several specific actions have been undertaken in the context of implementation of 
the Science and society action plan
67. In particular,  
– A  High Level Strata Group on Ethical Values and Science has been set up to discuss 
methodologies to analyze underlying ethical values in the ERA. The Group will present its 
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final report in 2005. 
–  The Forum of National Ethics Councils (NEC Forum) consists of the chairpersons and 
the secretaries of the national ethics councils. The President of the European Group 
on Ethics (EGE) and the President of the Bureau of COMETH (Council of Europe) are 
invited to the meetings. Established in 2003 involves now has representatives from all 
25 EU Member States. It is an independent informal platform for exchange of 
information, experience and best practices on issues of common interest in the field 
of ethics and science. The forum has in 2004 exchanged view on working methods of 
the committees and addressed the specific issue of creation of human animal hybrids. 
–  A Conference "Research Ethics committees in Europe: facing the future together" took place 
in Brussels on 27-28 January 2005. This event was the first of its kind and gathered together 
around 450 representatives of European research ethics committees (RECs), which 
evaluate, at local or regional level, any type of research protocols involving human beings. It 
was the first Conference on REC working activities68.  
–  A feasibility study for setting up an information and documentation system on ethics in 
research was conducted in 2004. 
–  The Global Forum on Bioethics in Research provides a venue for delegates from developing 
and developed countries to debate the ethical issues surrounding international collaborative 
research carried out in developing countries. The next Forum took place in Malawi on 16-18 
March 2005. It focused on what happens once the research is over, examining ethical 
debates on post-trial access to drugs, devices, or vaccines 
–  Capacity building on ethics committees in developing countries: the European and 
Developing Countries Clinical Trials Partnership (EDCTP) is conducting research (clinical 
trials) in developing countries that often have no local ethics committees to approve the 
research conducted on human beings. Cooperation has been established with the US 
National Institute of Health (NIH), the Magnus Warren Centre for clinical trials to jointly 
organize training workshops in developing countries that are of particular interest for EDCTP. 
Further actions are foreseen in 2005 to facilitate the networking of those EU centres that 
have specific activities on capacity building and training on ethics in developing countries. 
–  Dialogue with China: China has achieved the first fusion of an animal cell and a human cell 
in summer this year. China is strong in stem cell research and is certainly a global player. 
Several SARS trials are taking place in China. It is intended to create a network of focal point 
in the different MS and candidate countries to discuss the relation to China in ethics. A 
network of institutes of Asian studies, ethicists etc. may be created, twining single partners 
with partners in China. A workshop will take place in the second half of 2005 
–  Several projects are under negotiation from last call for proposals related to “Research into 
ethics”. Topics covered in the proposals include: nanotechnology, human-animal chimera, 
robotics, pre-implantation genetic diagnosis, capacity building in ethics in dev. Countries, 
education on bioethics for PhD students (biotechnology), training for members of research 
Ethics Committees etc. 
–  Several projects are under negotiation from last call for proposals in life sciences and health 
communication for promoting the awareness of scientific topics among different actors from 
Europe with a strong international dimension 
2.2.2.  Governing EC funded research in Life Science and Biotechnology 
In order to ensure that fundamental ethical principles are respected and the ethical, 
legal, social and wider cultural aspects are taken into account at the earliest possible 
stage of Community –funded research in Life Sciences and Biotechnology, involving 
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the general public to the greatest extent possible, the Commission has taken a 
number of actions, including: 
–  Establishment of ethical rules for FP6, 
–  Reinforcement of the ethical review, 
–  Integration of the analysis of the ethical, legal and social and wider cultural aspects (ELSA) 
into research projects under Priority 1 "Life sciences, genomics and biotechnology for health" 
and Priority 5 “ Food quality and safety” by encouraging both the participation of social 
scientists and civil society ( e.g. NGO ) in the project and the engagement of scientist in 
public dialogue, 
–  Supporting specific actions to promote the debate on ethical, legal, social and wider cultural 
aspects of Life Sciences and Biotechnology have been launched. 
2.2.3.  Ethical review in Community supported-research 
The number of research proposals undergoing ethical review in 2004 was almost 
double the number reviewed in 2003 (see Table 1). 
Table 1 
Number of proposals received for Ethical Review 
January – December 2003 
Number of Ethical Reviews exercises 
carried out 
Number of Proposals 
5 83 
   
January – December 2004 
Number of Ethical Reviews carried out  Number of Proposals 
5 153 
One reason for this sharp increase is greater awareness amongst project officers of 
the ethical review process, resulting in better briefing of scientific evaluators on 
identification of proposals involving sensitive ethical issues. 
2.2.3.1.  Overview2003-2004 
Ethical review took place on 5 occasions during 2004. The main “customers” for 
ethical review remain Priorities 1, 2 and 3 but 2004 has seen a significant increase in 
the numbers of proposals relating to Policy Support and NEST research calls. (See 
Table 2)  
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Table 2 
Total FP6 proposals having an Ethical Review 2003/04
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2.2.3.2.  Ethical review in 2005 
Current indications are that the number of proposals submitted for ethical review in 
2005 will show another significant increase over those submitted in 2004. The ethical 
review in April 2005 had around 90 proposals to be reviewed in comparison with the 
69 proposals reviewed in March 2004 (where the largest number of proposals was 
reviewed). 
2.2.3.3.  Issues of major significance on ethics emerging from the ethical review 
When considering the issue of ethics in the Framework Programme, it is clear that 
the issue of research involving hES cells is of importance. However, it is also worth 
noting that figures of December 2004 show that out of the 236 proposals submitted 
to the ethical review process, only 3 involved the use of hES cell ( existing hES cell 
lines) (i.e. 1,3%). Across the whole of the FP6 research agenda, many other 
significant and important ethical issues have been identified and addressed through 
the Commission’s ethical review process such as persons unable to give consent, use 
of non –human primates, use of genetic information etc .  
2.2.4.  Stem cells research 
Stem cell research is one of the promising areas of biotechnology that is currently 
receiving important investments in terms of financial and human resources in both 
private and public sectors. However, when this research involves the use of human 
embryos it raises the question of ethical values at stake and of the limits and 
conditions for such research. An intense public and political debate continues in 
many countries concerning the future of stem cell research and therapy. In the last 3 
years, Europe has seen a boom of new national legislation in this area. 9 EU Member 
States have passed specific legislation regarding human embryonic stem (hES) cell 
research between 2001 and mid- 2004. The recent scientific breakthrough regarding  
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the technique of therapeutic cloning, published be research team in South Korea in 
May 2005, has reopened the debate worldwide 
–  REGULATION OF HUMAN EMBRYONIC STEM CELL RESEARCH IN EU MEMBER 
STATES
69 
•  9 Member States (Belgium, Denmark, Finland, France, Greece, Spain, the Netherlands, 
Sweden, and United Kingdom) have a law allowing the procurement of human embryonic 
stem cells from supernumerary embryos. 2 MS (Belgium and United Kingdom) also allow 
the creation of human embryos for research purposes or for the procurement of stem cells. 
Somatic cell nuclear transfer (the so-call therapeutic cloning) is also allowed in these 
countries as well as recently in Sweden. Finland is discussing this last issue. 
•  4 Member States (Estonia, Hungary, Latvia, Slovenia) have a law on medically assisted 
reproduction that does not exclude some research activities on supernumerary embryos but 
without specific reference to hES cell research. 
•  2 Member States (Germany, Italy) prohibit the procurement hES cells from human embryos 
by law but not the importation of hES cell lines. Germany has established by law the 
conditions for the importation of these cell lines. 
•  3 Member States (Austria, Lithuania, Poland) prohibit the procurement of embryonic stem 
cells from human embryos by law. 
•  5 Member States (Czech Republic, Luxembourg, Ireland, Malta, Portugal, The Republic 
of Cyprus, Slovak Republic), have no specific legislation. 
For its part, following the FP6 1
st call for proposals, the Commission is supporting 25 
research projects, with a total EC contribution of around €160 millions, that involve 
at least one component of stem cell research. More than 90% of these projects 
involve the use of human stem cells from adult origin. Only 2 of these projects 
involving components of human embryonic stem cell (the use of existing hES 
cell lines). These 25 projects aims to develop new stem cell based therapies (often 
called regenerative medicine or cell based therapies), to use stem cells lines in drug 
development at pre-clinical stage and in toxicology, to understand human 
development and the basic mechanisms of cell differentiation and proliferation.  
Figures from the FP6 2
nd call for proposals, show that the Commission is expected to 
support around 17 projects with at least 1 component of stem cell research. This 
represents an EC contribution of around € 110 million. As in the 1
st call, more than 
90% of these projects involve the use of human stem cells from adult origin. Only 1 
of these projects involves a component of hES cell research (use of existing hES 
lines). 
A number of Member States including UK, Sweden and Spain are engaging in the 
establishment of public stem cell banks. The stem cell bank intends not only to 
provide high quality starting materials to facilitate the development of stem cell 
research, but, in providing a centralised resource for researchers, it will optimise the 
use of existing human embryonic stem cell lines and may reduce the use of human 
embryos for the development of new stem cell lines by individual teams. 
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In the context of the decision-making process of FP6, the Commission has 
committed itself to support the establishment of a European registry of hES cell 
lines, similar to the National Institute of Health (NIH) registry in the USA. Support 
for such a registry, which would allow an ethical tracking of existing hES cell lines 
in Europe and their optimal use, has been the subject of the 2nd and 3rd calls for 
proposals in Priority 1. In both cases, the proposals received were found by the 
evaluators to be of insufficient quality to be funded. Because the Commission 
attaches great importance to this subject, it will be reopened for proposals in the 4th 
call for proposals in the course of 2005. 
2.2.5.  The European Group on Ethics in Science and New Technologies 
The European Group on Ethics in Sciences and New Technologies (EGE) is a 
neutral, independent, pluralist and multidisciplinary body. It advises the Commission 
on all ethical questions related to Science and New Technologies in connection with 
the preparation and implementation of Community legislation or policies, acting 
either at the direct request of the European Commission or other Commissioners. The 
Parliament and the Council may also draw the Commission’s attention to the need 
for ethical advice in these fields. 
The EGE has issued Opinions on a wide range of ethical issues in the life sciences, 
from labelling food derived from modern biotechnology (N°5) to stem cell research 
(N°15). These Opinions are all available on the EGE Website
70. 
The current mandate expired at the end of March 2005 and a Commission decision 
on a revised mandate for the EGE for the next 4 years will be adopted beginning of 
May 2005. The end of the current mandate provided the opportunity to strengthen the 
status and role of the EGE. The new mandate extends the EGE membership from 12 
to 15 in order to include members from the new Member States and to bring in new 
competences. Another major improvement envisages the production of shorter 
Opinions or Statements that respond to scientific and technological developments in 
a more timely manner. In order to rationalise the functioning of the EGE and to 
facilitate meeting participation for the members, two-day meetings will be organised. 
Finally, in order to formalize and increase the transparency of the nomination 
procedure of the EGE members a call for expressions of interest was launched on the 
Internet. 
2.3.  CONFIDENCE IN SCIENCE-BASED REGULATORY OVERSIGHT  
2.3.1.  Review of the pharmaceutical legislation 
Following the adoption of the new Community Pharmaceutical legislative framework 
and its publication on 30 March 2004, the focus of work has been on its 
implementation and the introduction of implementing measures and guidelines. 
These measures include a Commission Regulation on incentives for Small and 
Medium-sized Enterprises (SMEs) in their dealings with the European 
Medicines Agency (EMEA) including 
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•  reductions and deferrals for a number of fees; 
•  easier access to scientific advice from the Agency; 
•  special incentives for companies developing orphan medicinal products; 
•  taking-over of certain administrative services (e.g. translations); 
•  tailored administrative support with the establishment of a new “SME office” 
within the EMEA; 
•  publication of a User Guide, providing an overview of relevant Community 
legislation and incentives for SMEs in the pharmaceutical sector. 
Public consultation, including a workshop with industry, on the proposal was 
concluded on 26 November 2004. Once adopted, the Regulation should apply with 
the full entering into force of the new pharmaceutical legislation, i.e. by the end of 
November 2005. 
In addition, the Commission adopted a proposal for a Regulation on paediatric 
medicines on 29 September 2004
71. This will provide a number of incentives to 
industry to develop medicines specifically for use in children, including enhanced 
intellectual property rights. 
Finally, although the formal G10 Medicines process
72 came to an end with the last 
meeting of the High Level Group of 3
rd June 2004, a number of recommendations, 
primarily concerning national competence, remain to be implemented. These are 
being taken forward in a new Commission industrial strategy for the pharmaceutical 
sector 
73. 
2.3.2.  Genetically Modified Organisms (GMOs) legislation 
2.3.2.1.  Implementation of the new regulatory framework on GMOs 
The new legal framework on GMO has entered into application, namely: 
•  Directive 2001/18/EC  on the deliberate release into the environment of 
genetically modified organisms, governing the placing on the market of GMOs 
for cultivation, import or processing into industrial products, as well as deliberate 
release for research purposes. It has replaced Directive 90/220/EC and applies 
since October 2002.   
 
With the exception of Greece, to date all Member States have fully communicated 
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their implementation measures for Directive 2001/18/EC. These are currently 
being assessed by the Commission for their conformity. 
•  Regulation (EC) No 1829/2003 on genetically modified (GM) food and feed, 
governing the placing on the market of GMOs intended for food or feed and of 
food or feed products containing, consisting of or produced from GMOs
74. Where 
a food or feed product contains or consists of GMOs, the applicant has a choice: 
(1) either the application in its entirety is uniquely subject to this Regulation, 
applying the "one door, one key" principle, in order to obtain authorisation for 
the deliberate release of a GMO into the environment - in accordance with the 
criteria laid down by Directive 2001/18/EC - and for the use of this GMO in food 
or feed products - in accordance with the criteria laid down by Regulation (EC) 
No 1829/2003
75; or (2) the application is split, one part being submitted under 
Directive 2001/18/EC and the other part Regulation (EC) 1829/2003.   
 
Regulation (EC) No 1829/2003 on GM food and feed is fully applicable since 18 
April 2004. Detailed rules on the implementation of this Regulation were adopted 
on 6 April 2004 with Commission Regulation (EC) No 641/2004. These rules 
refer to new applications for authorisation of GM food and feed, the notification 
of existing products and adventitious or technically unavoidable presence of GM 
material. Detailed guidance for the applicant concerning the data to be submitted 
for the risk assessment of GM plants and derived food and feed has been adopted 
by the European Food Safety Authority on 24 September 2004. 
•  In addition, GMOs and food and feed products produced from GMOs placed on 
the market must also comply with labelling and traceability requirements. These 
requirements are found in Regulation No (EC) 1829/2003 on GM food and feed 
and in Regulation (EC) 1830/2003 concerning the traceability and labelling of 
genetically modified organisms and the traceability of food and feed products 
produced from genetically modified organisms and amending Directive 
2001/18/EC. Regulation (EC) No 1830/2003 was adopted on 22 September 2003 
and entered into force on 7 November 2003. Its subsequent application was 
dependent upon the publication of an implementing measure, following its 
adoption via comitology, establishing a system for the development and 
assignment of unique identifiers to GMOs. This system was laid down in 
Commission Regulation (EC) No 65/2004, which was published on 16 January 
2004. Regulation (EC) No 1830/2003 was fully applicable 90 days later (15 April 
2004) in accordance with its Article 13(b). A Commission Recommendation 
(2004/787/EC) establishing guidance on sampling and testing was adopted on 4 
October 2004 and published on 24 November 2004 completing the necessary 
implementing measures under the Regulation. 
•  In enforcement of the above Community legislation on GMOs, the Commission 
has adopted a decision aimed to avoid that maize products produced from the non 
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authorised GM Bt10 maize are placed of the Community market
76. The decision 
applies to corn gluten feed and to brewers grains containing or produced from GM 
maize. Member States shall allow the first placing on the market of the above 
products only where accompanied by an original analytical report based on a 
suitable and validated method for the event-specific detection of GM Bt10 maize, 
issued by an accredited laboratory and demonstrating that the product does not 
contain Bt10 maize or feed produced from Bt10 maize. The decision also provides 
that Member States have to take all the appropriate measures to verify the absence 
of Bt10 maize in products already on the market. 
•  Finally,  Directive 2002/53/EC and Directive 2002/55/EC governing the 
marketing, and - as a consequence - the commercial cultivation, of seeds of GM 
plant varieties throughout the Community. According to these Directives, the 
Commission is required to inscribe in the Common Catalogue any such varieties 
which have been added to national catalogues. The GM seed varieties shall only 
be accepted for inclusion in a national catalogue after having been authorised in 
accordance with the above Community legislation.  
2.3.2.2.  State of play on GMO authorisations  
A) Applications under Directive 2001/18/EC 
Directive 2001/18/EC covers the approval of GMOs for import and industrial 
processing as well as cultivation. The Directive also covered approval for use in feed 
but under the new regulatory framework, this has subsequently been transferred to 
Regulation (EC) No 1829/2003 on GM food and feed from its date of application (18 
April 2004). However, certain applications for GMOs including their use in feed that 
were submitted under Directive 2001/18/EC prior to this date will continue to be 
approved under the Directive during a transition period according to the transitional 
measures laid down in Article 46(3) of Regulation (EC) No 1829/2003 on GM food 
and feed. 
Eleven applications out of the 25 submitted under Directive 2001/18/EC included 
requested uses as feed and were to be transformed into applications under Regulation 
(EC) No 1829/2003 on GM food and feed in accordance with its Article 46(3) given 
that the assessment reports required under Article 14(3) of the Directive had not been 
received by the Commission before the date of application of the Regulation. 
One product (NK603) has been approved in 2004 and two others (GT73 and 
MON863) are at an advanced stage of the approval procedure. Other applications are 
at different stages of the approval processes and some of them are currently being 
considered by the European Food Safety Authority (EFSA).  
B) Application under Regulation (EC) No. 258/97 on novel foods and Regulation 
(EC) No 1829/2003 on GM food and feed 
In 2004, two products (Bt 11 sweet maize and NK603 maize) were approved under 
the normal authorisation procedure of Regulation (EC) N° 258/97 on novel food. The 
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authorisation process is on-going for the remaining applications for authorisation of 
GMOs pending under Regulation 258/97 (i.e. GA 21 maize and MON863 maize). 
All of these authorisations are upgraded to the standards of the new regulatory 
framework, in particular concerning the labelling and traceability requirements. 
In accordance with Article 46(1) of Regulation (EC) No 1829/2003 on GM food and 
feed, applications under Regulation (EC) N° 258/97 on novel food for which the 
assessment report provided for under Article 6(3) of this Regulation had not been 
forwarded to the Commission before 18 April 2004, were transformed into 
applications under Regulation 1829/2003 on GM food and feed.  
In addition, a series of new applications for authorisation of GM food and feed have 
been submitted under Regulation (EC) No 1829/2003 on GM food and feed since it 
became applicable on 18 April 2004. EFSA has given a positive opinion on one of 
these applications on the 3 of March 2005 (1507 maize) and is currently conducting 
the risk assessment of the remaining applications. 
The new regulatory framework has also contributed by a notification procedure to 
further clarify which GM food and feed could already be legally placed on the 
market in the EU before the entry into force of Regulation (EC) No 1829/2003 on 
GM food and feed. Following this notification procedure, 26 GM products were 
entered in the Community Register on GM food and feed on 18 April 2005. With 
the entry into the Register, these products may stay legally on the Community market 
for a time period between 3 and 9 years, after which a renewal of the application for 
authorisation is necessary. The publication of the Register also allows withdrawing 
formally the authorisation of products for which no notification has been submitted.  
C) Directive 2002/53/EC on the common catalogue of varieties of agricultural plant 
species 
On 8 September 2004, the Commission has approved the inscription of 17 GM 
varieties derived from MON 810 maize in the Common Catalogue of agricultural 
plant species. The GM maize varieties will be the subject to the labelling and 
traceability requirements as established in Regulation 1830/2003 and in the seed 
legislation. 
2.3.2.3.  The Community Reference Laboratory for GM Food and Feed 
By the implementation date of Regulation (EC) No 1829/03 on GM food and feed 
the Joint Research Centre was ready to operate the “Community Reference 
Laboratory” (CRL) in the context of the GM Food and Feed Regulation. The CRL in 
the meanwhile has established a key reference position within the EU regulatory 
framework and has been instrumental in building up consumer confidence, 
particularly with respect to labelling and traceability.  
"Community Reference Laboratories" (CRLs) have been designated in different 
Community Decisions, Directives and Regulations. Whereas normally the task of 
CRL is assigned to a (consortium of) National Laboratory (-ies), the Joint Research 
Centre has been nominated “CRL” because Council and Parliament wished to benefit 
from the JRC’s expertise in the area of Genetically Modified Organisms (GMOs). 
The Community Reference Laboratory for GM Food and Feed was established by  
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European Regulation (EC) No 1829/2003 on genetically modified (GM) food and 
feed, and started its operations on 19
th April 2004. 
The CRL is assisted by a consortium of 75 national GMO enforcement control 
laboratories, from each of the 25 Member States of the EU, established in the 
existing European Network of GMO Laboratories (ENGL).  
Its main task is the testing and validation of the methods for detection and 
identification of the transformation events but it is also responsible for the 
distribution of control samples. At the end of the validation process, evaluation 
reports are submitted to the European Food Safety Authority. Regulation (EC) No 
641/2004 defines the implementing measures to comply with the GM Food and Feed 
regulation.  
During 2004 a total of thirty-five dossiers have been submitted to the CRL. These 
concern applications and notification of GMOs of various nature (superior plants, 
fermentation products) and species (maize, soybean, rice, sugar beet, oilseed rape, 
cotton). The validation of a quantitative event-specific method of detection was 
completed for the following GMO maize lines: NK603, GA21, MON 863 and TC-
1507. For these studies, a full validation report together with a detailed validated 
protocol was compiled
77.  
All updated versions of the documents are published in the CRL website
78. 
The expertise of the CRL has also been demonstrated in the alert reaction of the 
European Commission in the case of advertent release of unapproved maize of the 
BT10 event in the EU. It was responsible for the in-house validation and subsequent 
approval of a method that detects small traces of BT10. This method is the only one 
approved in the Community for certifying that maize commodities are free of BT10. 
2.3.2.4.  National ‘safeguard clauses’ 
During the late 1990s, a number of Member States (Austria, Luxembourg, Germany, 
France and Greece) invoked the ‘safeguard clause’ under Article 16 of Directive 
90/220/EEC to provisionally ban the placing on the market of certain GMOs (maize 
and oilseed rape) in their territories (Annex II).  
In December 2003, the Commission requested the above Member States to re-
consider their pending safeguard clauses in view of the new regulatory framework 
and if necessary, to re-submit them under Article 23 of Directive 200/18/EC (which 
replaced Directive 90/220/EEC). In view of this request, Greece and Austria 
submitted, in January 2004, further information in support of their bans. This 
additional information potentially impacted on all eight cases and was submitted to 
EFSA for opinion. EFSA concluded, on 8 July 2004, that the additional information 
did not invalidate the original risk assessments for the products in question.  
Following the opinions of EFSA, aligned with the new regulatory framework draft 
decisions requesting Member States to withdraw their national measures were 
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submitted to the Regulatory Committee for opinion. The Regulatory Committee, on 
29 November 2004, failed to reach qualified majority either in favour or against any 
of the draft decisions. Subsequently, in April 2005, the Commission adopted 
proposals for Council Decisions relating the measures taken. The Council has three 
months to act. 
In January 2005, Hungary invoked Article 23 (safeguard clause) of Directive 
2001/18/EC to provisionally prohibit the production, use and distribution of sowing 
seeds of in-bred lines and hybrids originating from the MON 810 maize line 
79, along 
with its importation into the territory of the Republic of Hungary. The ban extends to 
plants originating from cross-breeding with any traditionally improved maize 
varieties and lines. It does not apply to the use of MON 810 maize in the food/feed 
production chains, nor does it apply to transportation across Hungary without 
packaging and any further treatment if it is guaranteed that such maize is not released 
into the environment. The Commission has requested an opinion to EFSA, following 
which a decision will be taken in accordance with the regulatory procedure. 
With respect to the national safeguard clause (Article 12) invoked by Italy under 
Regulation N° 258/97, further to the ruling of the European Court of Justice (case C-
236/01) the regional Court of Justice of Lazio has cancelled the Italian decree of 
August 2000.  
Poland has submitted on 31 March 2005 an application for the introduction of a 
temporary two year ban on the use and placing on the market of seed material from 
genetically modified varieties of corn line MON 810 (inscribed in the Common 
Catalogue of agricultural plant species on 17 September 2004). This application is 
based on article 16(2) of Directive 2002/53/EC on the common catalogue of 
agricultural plant species. The application shall be dealt with under the regulatory 
committee procedure which is foreseen for seeds of genetically modified varieties. In 
the meantime the marketing of seeds of the varieties concerned is still permitted in 
Poland. 
Greece prohibited for a period of two years the marketing of seeds of 17 varieties 
from genetically modified hybrids of maize included in the common catalogue on 17 
September 2004. The measure is taken on the basis of article 18 of Directive 
2002/53/EC and was notified to the Commission on 4 April 2005. The national 
prohibition applied by Greece will be dealt with under the regulatory committee 
procedure which is foreseen for seeds of genetically modified varieties. According to 
the Directive, a decision shall be taken within a period of 3 months. In the meantime, 
marketing of the seeds of the varieties concerned is prohibited in Greece. 
2.3.2.5.  Co-existence of GM crops with conventional and organic crops 
In 2003, the European Parliament and the Council adopted a new article to Directive 
2001/18/EC (Article 26a) endorsing the Commission position that co-existence 
would be best managed at national or regional level. Several Member States and 
Regions are now developing their own co-existence measures.  
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Under these circumstances, when the measures in question consists of technical 
regulations in the sense specified by Directive 98/34/EC laying down a procedure for 
the provision of information in the field of technical standards and regulations, and 
by the case-law of the Court of Justice in the area, these measures must be notified to 
the Commission at the draft stage.  
Since late 2003, the Commission has received a number of these co-existence 
measures. In most cases, the Commission issued a detailed opinion (Article 9(2) of 
Directive 98/34/EC) according to which the draft measures presented aspects that 
could possibly create barriers to the free movement of goods within the internal 
market. A dialogue between the Member States in question and the Commission was 
initiated in these cases; the Commission encouraged those Member States to take 
better account of its Recommendation on coexistence (Recommendation 
2003/556/EC). This exchange provided the opportunity to clarify certain points. 
–  Coexistence measures notified to the Commission to date under Directive 98/34/EC 
(on provision of information on technical standards and regulations): 
•  Notification 2003/200/Autriche – Carinthie : Le texte adopté a été reçu le 01/02/05. La 
procédure de notification est terminée.  
•  Notification 2003/236/Italie (semences importées des pays tiers) : Après une réunion, le 
12/11/04, entre les autorités italiennes et les services de la Commission, l’Italie a confirmé 
son intention de modifier le texte du projet dans le sens demandé. 
•  Notification 2003/475/Autriche – Salzbourg : Salzbourg a transmis sa réponse à l’avis 
circonstancié mais a adopté le texte avant de recevoir la réaction de la Commission sur 
cette réponse.  
•  Notification 2004/133 et 241/Allemagne : La procédure de notification terminée 
•  Notification 2004/311/Autriche – Tyrol : La réponse de l’Autriche à l’avis circonstancié a 
été jugée satisfaisante. Communication à l’Autriche le 8 mars 2005 
•  Notification 2004/393/Danemark: Il s’agit d’une loi cadre qui ne contient pas de règles 
techniques. Le premier règlement d’application a été notifié sous la référence 2005/546/DK 
•  Notification 2004/426/Luxembourg: Un avis circonstancié a été envoyé le 25/01/05. En 
attente de la réponse 
•  2004/459/Autriche – Burgenland: Un avis circonstancié a été envoyé le 31/01/05. En 
attente de la réponse 
•  2004/538/Autriche – Vienne : Un avis circonstancié a été envoyé le 21/03/05. En attente 
de la réponse  
•  2004/546/Danemark : Observations ont été envoyées le 21/03/05 
•  2005/005/Autriche – Basse-Autriche : procédure interne de consultation en cours  
•  2005/012/Autriche – semences : n’est pas en infraction avec le droit communautaire  
Notification under Article 95 of the Treaty  
•  Upper Austria draft act prohibiting the cultivation of GM seeds and the used of GM 
animals and their releases: rejected by Commission Decision 2003/653/EC of 2.9.2003. The  
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regional Parliament of Upper Austria and the Austrian Federal government have appealed 
against the Commission decision to the Court of Justice 
In addition, the Commission is aware of a number of municipalities and regions in 
different Member States that have declared themselves “GMO-free”. As long as 
these declarations are a mere declaration of intent, a description of the status quo, or 
are based on voluntary agreements of all stakeholders concerned and do not imply a 
prohibition of the use of authorised products, they do not require notification by the 
Member State to the Commission. However, if those decisions are aimed at 
producing legal effects and result in a ban on the placing on the market of authorised 
GMOs, such measures might be in contradiction with Directive 2001/18/EC. 
–  European Regional and local authorities taking part in ( GMO-free zones) and regions 
movement 
–  (Last update: 10 February 2005; Source “Assembly of the European Regions”) 
An Europeans regions' network to prevent risks of genetic contamination in agriculture 
In a joint declaration of 4 November 2003, 10 European regions have asked the European 
Union to accept that European regions define their own territory or part of it as GM-free areas. 
These Regions are Toscana (I), Upper-Austria (A), Aquitaine (F), Basque Country (E), Bolzano 
(I), Limousin (F), Marche (I), Thrace (EL), Salzburg (A), Schleswig-Holstein (D), Wales (UK). 
Ten other regions – Highlands (UK), Burgenland (A), Lazio (I), Bretagne (F), Poitou Charentes 
(F), Emilia-Romania (I), Ile de France (F), Drama-Kavala-Xanthi (G), Sardegna (I) - have then 
joined the network 
On 4
th February 2005, the above twenty regions and local representative, signed a charter in 
Florence aiming to lay the foundations for their action plan to defend the right and the ability of 
EU farmers freely to choose between conventional, organic or transgenic farming. Since then, 
some additional regions have signed the charter 
With the exception of Upper Austria, the Commission has not yet received any 
formal notification of regional measures prohibiting the use of GMOs under the 
appropriate notification procedures. 
On 18 December 2003, the EP plenary adopted an own-initiative report calling the 
Commission for uniform and binding rules to be established at Community level on 
co-existence, including a proposal on Community-wide civil liability and insurance 
in respect of possible financial damage in connection with co-existence. 
On 16 December 2004 the Economic and Social Committee adopted an own-
initiative opinion on coexistence calling for rules on good professional practice to be 
set or harmonised at a high (i.e. Community) level, whilst remaining flexible enough 
to take account of the various conditions of cultivation and processing. 
The Member States are split with respect to their preference for Community 
legislation versus a continuation of the subsidiarity approach towards coexistence. 
Some Member States have repeatedly asked for harmonisation, while others have 
consistently opposed this.  
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•  Co-ordination network on co-existence 
Directive 2001/18/EC and Commission Recommendation 2003/556/EC provide for a 
coordination role of the Commission in the field of co-existence. In order to 
implement these obligations and commitments, and in line with conclusions of the 
Commission debate of 28 January 2004, the Commission is working on the setting 
up of a network group on co-existence as a forum in which Member States may 
present and discuss national or regional approaches to co-existence. The network will 
become operational within 2005. 
At the “Agriculture and Fisheries” Council of 18 October 2004, a number of Member 
States requested the Commission to set up a European Task Force on co-existence. 
•  Study on the implementation of co-existence legislation in the Member States 
In 2004, the Commission launched a study that should support the Commission in 
preparing the report on the experience gained in the Member States concerning the 
implementation of measures to address co-existence, which shall be presented in 
2005 to the Council and the European Parliament. The study should provide an 
overview and analysis of all relevant legislative and other approaches developed by 
the Member States, on national and regional level, with respect to co-existence. On 
the basis of the above report, the Commission will reflect on possible further steps to 
take on co-existence policy. 
•  Follow-up study on co-existence in crop and seed production 
In the JRC-IPTS study “New case studies on the co-existence of GM and non-GM 
crops in European agriculture” the seed and crop production of maize, sugar beet 
and cotton is investigated regarding co-existence in the same region The feasibility 
(technical and economical) of producing crops and seeds with different thresholds for 
the adventitious presence of GM crops is considered, with particular emphasis on the 
seed production sector in order to support the Commission decision on establishing 
labelling thresholds for seed production. The scope of the study covers the 
production up to the farm gate. Technical and economic consequences of threshold 
introduction beyond this stage are not included. 
The study identifies and maps geographical areas in several Member States where 
the adoption of GM maize, GM sugar beet, GM cotton is most probable (based on 
agronomical considerations). This will help to anticipate coexistence hotspots. The 
study also reviews the existing quantitative models on gene flow and will provide 
information on the level of validation of these models, in particular for the two 
models used in the JRC-IPTS co-existence study, namely MAPOD® and GeneSys®. 
•  Research Projects of Relevance under FP6 
Research regarding co-existence between conventional, organic and GM crop 
production is being addressed under the 6
th Framework Programme for Research. So 
far 2 projects have been funded with a total EC contribution of 17. 5 M Euro under 
Priority 5 “Food quality and safety” and Priority 8” Research for policy support”:  
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“Sustainable introduction of GMOs into European Agriculture” (SIGMEA project): This 
project aims to set up a science-based framework, strategies, methods and a practical toolbox 
for assessing ecological and economic impacts of GM crops and for effective managing of their 
development within European farming systems. It brings together the principal programmes and 
experts from UK, France, Italy, Denmark, Germany, Belgium, Slovenia, Switzerland, Spain, The 
Netherlands, Czech Republic, Poland and the Joint Research Centre. In the context of SIGMEA, 
JRC-IPTS will conduct in 2005 a specific study on the socioeconomic dimension of the Bt maize 
adoption by Spanish farmers (the only case so far in the EU of GM crops adoption). One of the 
objectives of this study is the evaluation of the economic performance of Bt maize versus its 
conventional counterpart. It will be the first study world-wide on the economic balance of a GM 
crop that considers potential costs derived from adopting measures to ensure co-existence 
–  “GM and non-GM supply chains: their co-existence and traceability” (Co-Extra): This 
project will study and validate biological containment methods and models for food and feed 
supply chain organisations. It will develop mathematic models for pollen emission and its 
impact on long distance dissemination as well as assess innovative detection methods for 
unknown GMOs and stacked GMOs. All methods and tools will be assessed from the 
technical as well as from the economic and legal points of view. 
3.  EUROPE IN THE WORLD - RESPONDING TO GLOBAL CHALLENGES 
3.1.  A EUROPEAN AGENDA FOR INTERNATIONAL COOPERATION  
3.1.1.  WTO dispute 
Following the establishment of the WTO panel in August 2003, the panellists have 
been appointed in March 2004 by the Director General of the WTO. Each party has 
filed three written submissions and one meeting of the parties with the Panel took 
place in June. The dispute will expand in 2005; the report of the Panel is expected in 
June 2005. In its written submissions as well as during the meeting with the Panel, 
the Commission, on behalf of the European Communities, has firmly rejected any 
concept of moratorium or undue delay in the processing of applications for 
authorisation. Rather, the Commission has explained the technical and scientific 
complexity of GMO issues, taking account in particular of the technical and 
scientific knowledge at the time of the occurrence of the alleged delays. From the 
Commission point of view, such complexity provides sound justification for the 
evolution of EU policy and regulation since the mid-nineties. The Commission has 
made it clear to the panel that in the EU, applications for authorisations are dealt with 
on a case by case basis and only products that fulfil the criteria laid down in the 
Community legislation can be approved. The Commission considers that the 
approvals granted under Directive 2001/18 or under Regulation (EC) N° 258/97 are 
irrefutable proofs that the case brought by the complaining parties is moot. 
3.1.2.  Cartagena Protocol on Biosafety. 
The Conference of the Party serving as the first Meeting of the Party took place in 
February 2004. The meeting has been a major success for the EU who has supported 
the Protocol since its birth. 
–  Main outcomes of the meeting 
–  adoption of a compliance procedure and mechanism  
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–  launch of negotiations on rules and procedure on liability and redress 
–  adoption of interim measures on documentation requirements for GMO shipments 
–  adoption of guidance to parties in their dealing with non-parties 
–  adoption of rules for the functioning of the Biosafety Clearing House 
–  adoption of an action plan for capacity building 
–  adoption of Guidance to the Financial Mechanism on support for the Protocol, 
–  adoption of a Medium-term programme of work for the next four meetings of the parties, 
–  adoption of a separate budget for the distinct costs of the Protocol. 
The EU participated to the 2nd Meeting of the Parties that took place in Montreal 
from 30 May to 3 June 2005.  
3.1.3.  Agriculture and Genetic Resources 
The Commission together with Member states, representatives of Civil Society 
organisations and the private sector, has completed a study to design an EU a pro-
poor strategy for green, red, white and blue biotechnologies in Developing 
countries. The final report was submitted by the consultants and the EU will finalise 
this proposal during 2005. The report identifies a number of choices for EU support 
to different clusters of developing countries, and crucial areas for EU 
interventions with respect to promoting pro-poor biotechnology. 
3.1.4.  Health 
Under FP6 poverty related diseases section has been funded projects focused on 
developing promising candidate interventions (vaccines, therapies and microbicides) 
against HIV, TB and malaria. The total budget allocated for this area, in FP6 is 
estimated at 221.5 million euro (1
st call: 73million €, 2nd call 27.5million €, 3
rd call: 
54 million €, 4
th call: 67 million €). 
Most of the projects are based on the collaboration with developing countries. In the 
1
st call of thematic priority 1 –under the poverty related diseases section, are 
participating as partners, in NoE and IP projects, the groups from: Ethiopia, Gabon, 
Guinea, Mali, South Africa, Sudan, Senegal, Uganda.  
Further support under FP6 was provided during 2004 for a special call for high risk 
and innovative projects (STREP/SSA) in drug and vaccine development for 
HIV/AIDS, TB and malaria. The total budget was 27.5 million €. There were 
selected 16 STREPs (14.2 million euro: for 7 projects in the field of HIV/AIDS, 5 in 
the field of malaria, 4 in the field of tuberculosis) and 5SSAs (1.3 million €: for 2 
projects in the field of HIV/AIDS and 3 in the field of TB). 
For the final call for poverty related diseases research, a budget of 67 million € will 
be provided.  
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The  European and Developing Countries Clinical Trials Partnership (EDCTP) 
initiative, with its head office located in The Hague (The Netherlands), was officially 
launched at the beginning of 2004 and an African Office of the EDCTP was opened 
in Cape-Town in July 2004. A balanced North/South partnership and the 
networking/coordination of participating European national programmes have been 
widely considered in the setting-up of the structure of this European pilot initiative 
which now operates within its own implementation structures, calls for proposals, 
evaluation and selection procedures. 
–  European and Developing Countries Clinical Trials Partnership (EDCTP) 
–  In the first EDCTP call, 9 projects on phase II /phase III clinical trials in the field of 
HIV/AIDS, tuberculosis and malaria drugs have been selected for funding and 6 senior 
fellowships were granted to African scientists. A total volume of about € 20 million is 
committed and 31 partners are concerned from African institutions representing 16 sub-
Saharan African countries.  
–  The South African Cochran database (A Clinical Trial Registry) has also been 
selected.  
–  In 2004 the operational basis for the networking and coordination of National 
Programmes was set up through the establishment of the European Network of 
National programmes (ENNP) 
–  In the annual “Work Programme 2005” for grants issued by DG AIDCO in April 2005, a 
specific call for supporting clinical trials sites selected by the EDCTP programme was 
earmarked 
Although the EDCTP is now operating, major issues still need to be addressed such 
as the necessity to attract further funds not earmarked for research (e.g. from the 
European Development Fund specific budget lines and the private sector), the need 
to consolidate the global dimension of the EDCTP (e.g. through international 
partnerships with the New Partnership for Africa’s Development (NEPAD), the 
International AIDS Vaccine Initiative (IAVI), the World Health Organisation 
(WHO), Glaxo Smith & Kline (GSK), Medicines for Malaria Venture (MMV) or the 
recently founded Global HIV Vaccine Enterprise (GVE), the African participation 
and ownership within the EDCTP and finally the questions related to participating 
Member States’ medium and long term commitments vis-à vis EDCTP 
A project supporting the construction of new infrastructures of bio-safety level 3 and 
4 laboratories for studying highly contagious diseases (“EUTRICOD”) including 
viral hemorrhagic fevers was initiated involving the Republic of Ghana and Uganda. 
During 2004, additional funds were also made available to support North/South 
collaborative research projects on further “neglected tropical diseases”, on child 
survival, on reproductive health and on “health systems research”. 
A number of initiatives on capacity building on ethics in developing and emerging 
countries are being supported by the Commission. Four African institutions together 
with two European organizations and the World Health Organization have come 
together to foster networking of medical research ethics committees in Africa: 
Networking for Ethics on Biomedical Research in Africa (NEBRA). As a first step, 
the project will identify existing ethics review capacity and needs in 15 African 
countries. A series of training and capacity building workshops on ethical review of  
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clinical trials have been launched in several developing countries through the project 
“European and Developing Countries Ethics Partnership”. 
The European Group on Ethics issued Opinion (N°17) on the ethics of clinical 
research in developing countries which has been published and is available online
80. 
A project has been launched addressing the issue of genomics and benefit sharing 
with developing countries. 
3.1.5.  Food safety 
A “food quality and safety platform” promoting science and technology dialogue 
between EU and Latin America (in the context of the ALCUE bi-regional dialogue) 
has been initialled with the support of the Commission. It aims at a) facilitating 
information development and knowledge sharing on factors influencing food quality 
and safety wit the objective of stimulating enhanced regulations and practises, 
b)  promoting a greater convergence in RTD and elaboration of food quality and 
safety policies, c) synergizing technology transfer and trade and d) optimising the 
utilization of cooperation resources.  
4.  IMPLEMENTATION  AND  COHERENCE  ACROSS  POLICIES,  SECTORS 
AND ACTORS 
4.1.  FORESIGHT ACTIVITIES  
4.1.1.  Study on biotechnology 
The European Parliament requested the Commission in late 2004 to “assess and 
conduct a cost-benefit analysis of biotechnology and genetic engineering, including 
GMOs. The aim of the study is to conduct a comprehensive assessment and cost-
benefit analysis of the opportunities afforded by, and the risks of, biotechnology and 
genetic engineering, including the medical and agricultural spheres, account being 
taken of the Lisbon strategy, the Copenhagen environment criteria and Agenda 21 
sustainable development”
81. 
Modern biotechnology is generally regarded as a key enabling technology with a 
potentially wide range of applications. However, recent studies suggest that the 
actual adoption and use of modern biotechnology across industrial sectors may be 
lower than expected three decades after the key scientific discoveries took place
82. 
The use of biotechnology in industrial processing is still largely limited to a few 
examples, genetically modified crops are hardly grown in Europe and promising 
applications such as stem cells are still in R&D phases
83. Modern biotechnology 
seems to have succeeded mostly in niche applications where it does not compete with 
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alternative technologies (a clear example is protein or antibody-based 
pharmaceuticals). 
Yet, the same studies acknowledge that data on the actual adoption of biotechnology 
and related economic, social and environmental consequences is very scarce and 
hampered by the lack of appropriate and updated statistics. This is why a profound 
analysis of the current state, and the opportunities and challenges of modern 
biotechnology for Europe is not available and cannot be performed without 
undertaking significant previous work. 
Evaluating the consequences, opportunities and challenges of modern biotechnology 
for Europe is important both for policy makers and industry. European policy 
strategies on economic growth, sustainable development and environmental 
preservation have been outlined in the past years. Understanding how the adoption of 
modern biotechnology in the various production sectors could contribute to the 
objectives of these strategies is a recognized need.  
The Commission recognises the potential value of carrying out a comprehensive 
study on biotechnology. The study will be executed by the Institute for Prospective 
Technological Studies of the Commission Joint Research Centre (JRC-IPTS) in close 
collaboration with the other services of the Commission.  
The Commission is currently defining the content and structure of the activity. The 
objective will be to provide a comprehensive assessment of the consequences, 
opportunities and challenges that applications of modern biotechnology present for 
Europe in terms of economic, social, and environmental aspects, having in mind 
major European policy goals, i.e. to become the most competitive and dynamic 
knowledge-based economy in the world capable of sustainable economic growth 
with more and better jobs and greater social cohesion and respect for the 
environment. 
It is expected that the whole activity, including a final symposium, will take up to 24 
months. 
4.2.  EMERGING ISSUES  
4.2.1.  Tissue engineering 
Human tissue engineering is an emerging, multidisciplinary biotechnology sector 
focusing on the regeneration of diseased human tissues. The development of this 
novel biotechnology promises to change medical practice profoundly and heralds 
new treatment possibilities for European patients. The hope is that human tissue 
engineered products will deliver superior treatments by improving the speed, extent 
and duration of healing compared to conventional treatments. However, legislation 
currently varies from one Member State to another. The lack of a clear and uniform 
regulatory framework leads to legal uncertainty and to a fragmentation of this 
emerging market. The European Commission has therefore announced that it would 
propose new legislation harmonising the authorisation procedures for human tissue 
engineered products.  
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In April 2004, the Commission services published a consultation paper on the future 
proposal for a harmonised regulatory framework on human tissue engineered 
products
84. This document outlined key issues to be addressed in future legislation 
and invited written comments from interested parties. Regulatory orientations were 
also discussed during a stakeholders’ conference.  
In addition, following a first report on human tissue-engineered products (hTEPs) 
published December 2003
85, JRC-IPTS finalised in 2004 a study analysing the 
potential economic, social and environmental impacts a future European level 
regulation on hTEPs could have
86. The study showed that Member States currently 
approach authorisation of hTEPs in very diverse ways, ranging from hTEPs not 
being regulated at all to being regulated as medicinal products. This situation results 
in differing safety, quality and efficacy standards and a fragmentation of the 
European market, which presents a hurdle to the competitive development of the 
sector. The tissue-engineering sector is a young and still developing sector, and thus 
has the opportunity to adapt to a changed regulatory environment. As the sector is 
characterised by fairly small manufacturers, including hospitals and tissue banks, 
specific support measures might be considered to avoid overly burdensome 
authorisation processes. The planned regulation could help to build trust in this new 
technology, thereby encouraging its acceptance in medical practice and 
reimbursement policies. It would thus indirectly target another major hurdle for the 
further development of tissue engineering. 
In light of this preparatory work, the principles and main elements of the legislative 
proposal have now been agreed upon. The key objectives are the following: 
–  To guarantee a high level of health protection for European patients treated with 
advanced therapies (gene therapy, somatic cell therapy, tissue engineering); 
–  To facilitate market access for advanced therapies, in particular tissue engineered 
products, by establishing a harmonised and tailored regulatory framework for their 
authorisation, supervision and post-authorisation vigilance; 
–  To foster the competitiveness of European undertakings operating in this field; 
–  To provide overall legal certainty, while allowing for sufficient flexibility at 
technical level, in order to keep the pace with the evolution of science and 
technology. 
Stakeholders will be consulted on the draft Regulation in May-June 2005. Adoption 
of the Commission proposal is foreseen for the last quarter of 2005. 
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Under the 1st call of Life sciences genomics and biotechnology for health 
programme 8 projects has been funded in tissue engineering field. 
Adult mesenchymal stem cells engineering for connective tissue disorders, from the 
bench to the bed side (Genostem). This IP (23 partners) launched in 2004, brings together 
experts from Molecular Biology, Cellular Biology, Biomechanics, Genomics, Proteomics, 
Bioinformatics and Molecular Medicine, for establishing an European international scientific 
leadership in stem cell regenerative medicine focus on connective tissue engineering based on 
autologous adult mesenchymal stem cells(MSCs). The project will: a) develop new technologies 
to generate biodegradable matrices, scaffolds and microcarriers; b) improve methods for gene 
transfer using original lentivirus or non viral delivery systems; c) develop a number of 
transplantation models of MSCs mimicking human pathological processes. 
4.2.2.  Genetic testing and related issues 
Genetic testing, its scientific, ethical, legal and social implications, have continued to 
be subject to debate both internationally and nationally. New legislation is underway 
in several EU Member States. Sweden is expected to adopt a new law in summer 
2005, which will address the use of genetic testing in employment, insurance and 
health care. The need for a bill has also been addressed by the German Minister for 
Health.  
For its part, the Commission, in response to the priority action stated in the second 
progress report on the Strategy for Europe on Life Sciences and Biotechnology, has  
•  has established an informal working group involving officials and experts from Member 
States to ensure exchange of information and to identify actions which should be addressed 
at EU level in order to assure the highest quality of genetic testing. The need for 
collaboration and exchange of information at EU level was confirmed at the two meeting 
organised so far in May 2004 and March 2005. A survey on national legislations and 
activities regarding genetic testing has been prepared. Discussion is continuing on the basis 
of an “open issues paper” summarizing the questions that should be tackled by the 
Commission and Member States. 
•  has started to analyse the directive 98/79/EC on in vitro diagnostic medical devices in 
the context of genetic testing and in particular regarding quality and performance assurance 
of genetic test devices. The results are expected early 2006; 
•  has implemented, under FP6, a Network of Excellence “EUROGENTEST”
87 addressing the 
issue of harmonisation, validation and standardisation of genetic tests. A public database 
including all laboratories in the EU that provide genetic testing (molecular, biochemical, 
cytogenetics) will be available early 2006; 
•  is supporting the  a series of activities to improve information and to network concerned 
parties in the field of rare diseases in the EU Public Health Programme
88. A number of 
research projects on genetic testing of rare diseases are funded under FP5 and FP6. So far 
the need for a referral system for rare and complex genetic diseases has been identified as 
an issue which need special attention 
                                                 
87  www.eurogentest.org 
88  http://europa.eu.int/comm/health/ph_threats/non_com/rare_diseases_en.htm 
http://europa.eu.int/comm/health/ph_projects/rarediseases_project_en.htm 
http://europa.eu.int/comm/health/ph_projects/action1_en.htm  
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An initiative on the protection of worker’s personal data in the employment 
context is expected to be launched in 2005. The initiative will also address the 
processing of genetic data. The European Group on Ethics issued Opinion (N°18) on 
the ethics of genetic testing in the work place which has been published and is 
available online
89. 
On 17 March 2004, the Article 29 Working Party (National Data Protection 
Authorities-DPAs) adopted a working document on the processing of genetic data
90. 
One of its main conclusions is that any use of genetic data for purposes other than 
directly safeguarding the data subject’s health and pursuing scientific research should 
require national rules to be implemented, in accordance with the data protection 
principles provided for in Directive 95/46. The processing of genetic data should be 
authorized in the employment and insurance fields only in very exceptional cases 
provided for by law, so as to protect individuals from being discriminated against on 
the basis of their genetic profile. The Working Party may revisit the working 
document in the light of experience acquired by DPAs and may decide to focus in 
detail on specific areas at a later stage, in order to keep in line with the technological 
developments linked to the processing of genetic data. 
The recommendation from the high level expert group “ETAN-STRATA”
 91, 
addressing the ethical, social and legal aspects of human genetic testing in research 
and healthcare applications, has been published in 19 EU languages
92.  
4.2.2.1.  Interface between in vitro fertilization techniques and pre-implantation genetic 
diagnosis (PGD).  
JRC-IPTS, together with the European Society of Human Genetics and the European 
Society for Human Reproduction and Embryology, organized a workshop in March 
2005 on the interface between in vitro fertilization techniques and pre-implantation 
genetic diagnosis (PGD), a new application of genetic testing that is taking off very 
quickly and with potential large impacts of many kinds. Different regulations, 
practices and lack of professional recommendations and guidelines may still lead to 
large differences across Member States. There seems to be many questions around 
the genetic services involved in assisted reproduction that could benefit from a 
European coordination effort, including the quality of these services. 
A key issue is the scientific claim that by genetic screening, the routine procedure of 
implantation of several embryos per woman can be reduced to implanting a single 
embryo, with potential large economic savings (by increasing efficiency) and 
reduction of multiple births. While not all scientists agree yet with this claim, the 
technology is likely to become routine in some clinics. Another key issue is the 
apparent generalisation of genetic testing of donors of sperm with very little control 
since most activities occur in the private sphere. It seems a fact that a few genetic 
profiles may be being used massively as donors.  
                                                 
89 http://europa.eu.int/comm/european_group_ethics/avis3_en.htm 
90  http://europa.eu.int/comm/internal_market/privacy/docs/wpdocs/2004/wp91_en.pdf 
91  http://europa.eu.int/comm/research/conferences/2004/genetic/recommendations_en.htm#top 
92  Translations in Chinese, Russian, Arabic and Japanese are foreseen in 2005.  
EN  48     EN 
Pre-implantation genetic diagnosis is affected by Directive 2004/23/EC of the 
European Parliament and of the Council of 31 March 2004 on setting standards of 
quality and safety for the donation, procurement, testing, processing, preservation, 
storage and distribution of human tissues and cells. The donation of eggs, sperm and 
embryo fall within its scope and so do the type of genetic screening performed, 
amount of clinical history of donors included, amount of genetic information and so 
forth. The European Society of Human Genetics (ESHG) and the European Society 
of Human Reproduction are currently providing input to a Commission’s guidelines 
document for implementation of the directive. The background document being 
prepared and the discussion at the workshop will tackle these issues.  
JRC-IPTS will launch an assessment of the current practices of pre-implantation 
genetic diagnosis in EU to define the needs in the area and assess potential options to 
solve them. Results will be available by mid 2006.  
4.2.2.2.  Pharmacogenetics 
Pharmacogenetics is the study of inter-individual specific genetic variation related to 
response to medicines. It is often said that pharmacogenetics (PG) might enable the 
pharmaceutical industry to significantly enhance the productivity of drug discovery 
and development, allowing also the re-evaluation of drugs that have failed because of 
low response rates in the general population. In health care, PG could help reduce the 
overall cost of disease management, minimizing adverse effects and improving 
therapeutic efficacy. As the applications of PG are relatively recent (although the 
term itself is some 50 years old), a comprehensive picture of the state-of-the-art in 
the EU in terms of research activities, commercial applications in drug development, 
PG-related market and industry structure and probable future developments has yet 
to emerge.  
JRC-IPTS, together with the European Society of Human Genetics, organized a 
workshop in 2004 with experts from different disciplines to review the field. The 
workshop concluded that the clinical application of PG has so far been overestimated 
and expectations have not yet been fulfilled. It has not moved yet to practical 
applications, except for very limited drug examples. There is uncertainty when 
estimating the possible impacts that a large development of PG applications could 
have on health care in Europe. There are multiple ways in which PG will influence 
health systems and various pressures which will in turn affect the successful 
implementation of PG. A paper including a detailed background document and 
conclusions of the workshop is under preparation for publication (available in 
September 2005). 
The workshop served to define the scope of an on-going JRC-IPTS study mapping 
the R&D situation of PG in Europe, identifying upcoming socio-economic issues and 
potential barriers to development and implementation of PG applications in clinical 
practice. The study includes the detailed cost-benefit analysis of two case studies of 
existing PG applications. The final report will be available by July 2005, and is 
expected to be presented in an OECD-organised meeting addressing challenges to 
health systems from pharmacogenetics, that will take place in October 2005 in 
Rome,.  
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The European Medicines Evaluation Agency (EMEA), currently addressing these 
issues, organised in November 2004 an expert meeting to discuss regulatory needs. It 
was stressed that no legislative provisions should be made before a wide-ranging 
consultation process with all relevant stakeholders has taken place. The importance 
of ensuring high quality and validation methods for pharmacogenetic tests was also 
stressed. 
A number of research projects promoting the development of pharmacogenetics in 
Europe are funded under FP6, such as the “Genome based therapeutic drugs for 
depression(GENDEP)”, an integrated project with 18 partners launched in 2004 and 
if successful will lead to validated pharmacogenomic methods for symptom 
improvement in depression, the prediction of response to psychiatric drug treatment 
and the reduction of adverse effects. 
4.2.2.3.  Bio-banks  
The establishment of human bio-banks
93 and access to information contained in them 
are important infrastructures for the development of genetic tests. A number of bio-
banks have been established worldwide
94. At the same time it has led to new ethical 
dilemmas which among others are under discussion in ethics committees at national 
and international levels. New specific legislations regarding bio-banks have been 
implemented in a few countries (Denmark, Norway, Iceland, Estonia and Sweden) 
and other countries are discussing legislative proposals or the need for specific 
regulation
95. 
The ability to optimise the use of bio-banks across Europe is an important foundation 
to ensure progress of European biomedical science including for the development of 
genetic testing and pharmacogenetics. However, effective collaboration is becoming 
increasingly difficult in a complex world where the principles governing public and 
private bio banks differ between countries. 
4.2.3.  Animal biotechnology 
Two complementary initiatives have been launched by the Commission in this area, 
at the end of 2004. A project aiming at stimulating an informed, public debate across 
Europe on farm animal cloning and to ensure public participation in the forming of 
                                                 
93  biological material from one or several human beings collected and stored indefinitely or for a specified time and 
whose origin can be traced to the human or humans from whom it originates 
94 UK  Biobankhttp://www.ukbiobank.ac.uk/ 
CARTaGENE http://www.cartagene.qc.ca/en/ 
GenomEUtwin http://www.genomeutwin.helsinki.fi/ 
Swedish Twin Registry http://www.mep.ki.se/twinreg/index_en/ 
Estonian Genome Foundation http://www.geenivaramu.ee/index.php?sho=main&lang=eng/ 
ecode Genetics  http://www.decode.com/ 
Umea University Medical Biobank http://www.biobanks.se/medical%20biobank.html/ 
Danish Twin Registy http://www.dtr.sdu.dk/?dideid=index&sprog=eng/ 
Genomics Collaborative, Inc.,http://wwwgenomidsinc.com/ 
European Prospective Investigation into Cancer and Nutrition (EPIC) http://www.iarc.fr/epic/ 
MRC/Cancer Research UK/BHF Clinical Trial Service Unit & Epidemiological Studies Unit 
http://www.ctsu.ox.ac.uk 
Neocodex http://neocodex.es 
Oxagen http://www.oxagen.co.uk 
95 http://europa.eu.int/comm/research/biosociety/bioethics/  
EN  50     EN 
policies has been launched under the thematic priority “Food quality and Safety”. 
The project will provide recommendations for regulation and guidelines covering 
research on farm animal cloning and its subsequent applications. Secondly, a 
prospective study on Animal Cloning and Genetic Modification and derived products 
has been launched by the Institute for Prospective Technological Studies (JRC-
IPTS). The study aims to provide a comprehensive picture of research and 
commercial activities involving animal cloning and/or genetic modification and 
current and future products obtained from these animals world wide; to identify the 
potential benefits, risks and socio-economic impacts; to compare the regulatory 
frameworks world-wide and to assess new policy implications of the developments 
of these technologies and of the commercialization of their products in the EU.  
4.2.4.  Converging sciences and technologies 
A high level expert group on Converging Technologies (the convergence of 
nanotechnology, biotechnology, information technology and cognitive science) was 
set up by the Commission at the end of 2003.The report of the EU expert group, 
entitled “Converging Technologies – Shaping the Future of European Societies”
 96, 
was discussed during a conference organised by the Commission in September 2004. 
The group and the participants to the conference have insisted on the new scientific 
paradigms and new scientific production modes relying on inter- and trans-
disciplinarity. The European expert group stressed the importance of specific societal 
needs that must be identified in order to take advantage of and preserve Europe’s 
cultural diversity and to create economic opportunity. Social sciences and humanities 
should provide orientation where Converging Technologies could disrupt traditional 
ways of life and should serve as intermediaries between political actors, researchers 
and society, and help to assess risks. The expert group suggested that research 
programmes at national and EU levels should include activities focusing on cross 
cutting and converging issues. A number of national conferences or events are 
already foreseen in the first quarter of 2005 and the Commission is reflecting on 
future actions in the context of the preparation of FP7. 
The European Group on Ethics has adopted Opinion (N°20) on the ethics of 
information and communication technology (ICT) implants in the human body. This 
Opinion is published and is available online
97. The ethical analysis addresses 
convergent technologies (ICT and life sciences) and responds to a number of human 
rights issues in this interdisciplinary field. 
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